AA



SURVEILLANCE REPORT

Influenza virus characterisation

Summary Europe, September 2019

Summary

This is the tenth and final report for the 2018–19 influenza season. As of week 39/2019, 205 947 influenza detections across the WHO European Region had been reported; 99% type A viruses, with A(H1N1)pdm09 prevailing over A(H3N2), and 1.2% type B viruses, with 86 of 165 (52%) ascribed to a lineage being B/Yamagata.

Since the July 2019 characterisation report[1], a further three shipments of influenza-positive specimens from EU/EEA countries were received at the London WHO CC, the Francis Crick Worldwide Influenza Centre (WIC). A total of 1 511 virus specimens, with collection dates after 31 August 2018, have been received.

The 85 A(H1N1)pdm09 test viruses characterised antigenically since the last report showed equivalent good reactivity with antisera raised against both the A/Michigan/45/2015 2018–19 vaccine virus and the A/Brisbane/02/2018 2019–20 vaccine virus. The 613 test viruses with collection dates from week 40/2018 genetically characterised at the WIC, including two H1N2 reassortants, have all fallen in subclade 6B.1A, defined by S74R, S164T and I295V HA1 substitutions; 564 of these viruses also have HA1 S183P substitution, often with additional substitutions in HA1 and/or HA2.

Since the last report, 37 A(H3N2) viruses successfully recovered had sufficient HA titre to allow antigenic characterisation by HI assay in the presence of oseltamivir; all were poorly recognised by antisera raised against the vaccine virus, egg-propagated A/Singapore/INFIMH-16-0019/2016. Of the 505 viruses with collection dates from week 40/2018 genetically characterised at the WIC, 399 were clade 3C.2a (with 43 3C.2a2, 17 3C.2a3, eight 3C.2a4 and 331 3C.2a1b); 106 were clade 3C.3a.

Ten B/Victoria-lineage viruses have been characterised in this reporting period. All recent viruses have HA1 amino acid substitutions of I117V, N129D, and V146I compared to B/Brisbane/60/2008 (clade 1A), a previous vaccine virus. Groups of viruses defined by deletions of two (Δ162-163, 1A(Δ2)) or three (Δ162-164, 1A(Δ3)) amino acids in HA1 have emerged, with the Δ162-164 group having subgroups of Asian and African origin. These virus groups are antigenically distinguishable by HI assay. Of 20 viruses from EU/EEA countries this season that have been characterised genetically, one has been clade 1A, two 1A(Δ2) and 17 1A(Δ3) (16 African and one Asian subgroup).

Nine B/Yamagata-lineage viruses have been characterised antigenically in this reporting period, giving a total to 23 for the 2018–19 season. All have HA genes that encode HA1 amino acid substitutions of L172Q and M251V compared to, but remain antigenically similar to, the vaccine virus B/Phuket/3073/2013 (clade 3) recommended for use in quadrivalent vaccines for the next northern hemisphere influenza season.

[1] European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, July 2019. Stockholm: ECDC; 2019. Available from: https://ecdc.europa.eu/sites/portal/files/documents/influenza-virus-characterisation-report-Jul-2019.pdf

This report was prepared by Rod Daniels, Burcu Ermetal, Aine Rattigan and John McCauley (Crick Worldwide Influenza Centre) for the European Centre for Disease Prevention and Control under an ECDC framework contract.

Suggested citation: European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, October 2019. Stockholm: ECDC; 2019.

Table 1 shows a summary of influenza virus detections in the WHO European Region reported to ECDC's TESSy database since the start of the 2018–19 season (weeks 40/2018–39/2019), with only 1 335 detections in weeks 21–39/2019. Since week 1/2019, the cumulative number of detections has increased from 18 049 to 205 947, with type A (98.8%) predominating over type B (1.2%) viruses which is a common pattern, unlike the 2017–18 season when type B predominated over type A at the start of the season and throughout most of it. Of the type A viruses subtyped (n = 77 296) and the type B viruses ascribed to a lineage (n = 165), A(H1N1)pdm09 (n = 44 179) have prevailed over A(H3N2) (n = 33 117) viruses and 86 of 165 type B viruses have been B/Yamagata-lineage. Overall, the ratio of type A to type B detections is dramatically increased compared with the 2017–18 season (0.8:1 to 86:1), and as the 2018–19 influenza season has progressed, the early prevalence of A(H1N1)pdm09 over A(H3N2) viruses has decreased such that levels observed in the two seasons have become comparable (57.2% in 2018–19 compared with 50.6% in 2017–18).

Table 1. Influenza virus detections in the WHO European Region from the start of reporting for the 2018–19 season (weeks 40/2018–39/2019)[a]

	Cumulative number of detections			Totals*		Totals for 2017-18 season*		
Virus type/subtype/lineage	Sentinel sources	Non-sentinel sources	Totals	%	Ratios	Number	%	Ratios
Influenza A	**21079**	**182485**	**203564**	**98.8**	**86:1**	**106003**	**44.1**	**0.8:1**
A(H1N1)pdm09	8761	35418	44179	57.2		23121	50.6	
A(H3N2)	7264	25853	33117	42.8	0.7:1	22568	49.4	1:1
A not subtyped	5057	121214	126271			60314		
Influenza B	**298**	**2082**	**2380**	**1.2**		**134618**	**55.9**	
Victoria lineage	13	66	79	47.9		301	1.9	
Yamagata lineage	50	36	86	52.1	1.1:1	15701	98.1	52.2:1
Lineage not ascribed	235	1980	2215			118616		
Total detections (total tested)	**21380 (55128)**	**184567 (>794311)**	**205947 (>849439)**			**240621 (903182)**		

*** Percentages are shown for total detections (types A & B [in bold type], and for viruses ascribed to influenza A subtype and influenza B lineage). Ratios are given for type A:B [in bold type], A(H3N2):A(H1N1)pdm09 and Yamagata:Victoria lineages.**

Since week 40/2018, 67 (3 since July) shipments of specimens (virus isolates and/or clinical specimens) from 36 centres across 30 EU/EEA countries have been received at the Crick Worldwide Influenza Centre (WIC). They have contained a total of 1 511 individual virus-related samples with collection dates after 31 August 2018 (Table 2). The proportions of received samples are similar to those reported to TESSy (Table 1) in terms of virus type and virus subtype or lineage. The genetic and antigenic characterisation data generated at the WIC for these viruses has been presented at the WHO influenza vaccine composition meetings for the northern hemisphere 2019–20 season (viruses with collection dates up to 31 January 2019) and the southern hemisphere 2020 season (viruses with collection dates from 1 February 2019). Recommendations emerging from these meetings, held 18–21 February and 23–27 September respectively, have been published [1, 2].

Table 2. Summary of clinical samples and virus isolates, with collection dates from 1 September 2018, contained in packages received from EU/EEA Member States since week 40/2018

MONTH / Country	TOTAL RECEIVED Seasonal viruses	A		H1N1pdm09		H3N2			B		B Victoria lineage		B Yamagata lineage	
		Number received	Number propagated[1]	Number received	Number propagated[1]	Number received	Number propagated[2]		Number received	Number propagated[1]	Number received	Number propagated[1]	Number received	Number propagated[1]
2018														
SEPTEMBER														
France	7					6	3	3					1	1
Spain	1			1	1									
Sweden	1			1	1									
OCTOBER														
Czech Republic	2			2	2									
Denmark	2					2	0	2						
Estonia	3	1	0	1	0	1	0	1						
Finland	2			1	1	1	0	1						
France	11			3	3	7	5	2					1	1
Germany	1					1	0	1						
Iceland	2					1	0	1					1	1
Ireland	3			2	1	1	0	1						
Latvia	1			1	1									
Netherlands	1					1	0	1						
Norway	29			12	8	14	0	8					3	1
Portugal	2			2	2									
Slovenia	1			1	1									
United Kingdom	3			1	1	2	0	2						
NOVEMBER														
Austria	4			1	1	3	1	2						
Belgium	5			3	2	2	0	2						
Bulgaria	1			1	0									
Croatia	1			1	1									
Czech Republic	1			1	1									
Denmark	12			8	8	3	0	3			1	1		
Estonia	3			3	1									
Finland	4			2	2	2	0	2						
France	17			10	10	7	4	2						
Germany	8			4	4	4	0	4						
Iceland	15			4	3	11	7	3						
Ireland	17			12	10	4	0	3					1	1
Italy	10			2	2	8	5	3						
Latvia	2					2	1	1						
Lithuania	5					5	0	4						
Netherlands	3			2	2	1	0	1						
Norway	26			14	13	12	1	10						
Portugal	1												1	0
Spain	8			2	1	6	0	2						
Sweden	1			1	1									
United Kingdom	15			6	6	7	2	2			1	0	1	1
DECEMBER														
Austria	4			2	2	2	1	1						
Belgium	6			2	1	4	0	2						
Bulgaria	9			5	4	4	0	4						
Croatia	8			6	6	2	0	1						
Cyprus	3			3	1									
Denmark	7			5	5	2	0	2						
Estonia	18	1	0	16	11	1	0							
France	33			17	17	14	10	4			1	1	1	1
Germany	11			5	5	6	0	6						
Greece	11			8	5	3	0	1						
Hungary	6			4	4	2	1	1						
Iceland	3			3	3									
Ireland	3			3	3									
Italy	1			1	1									
Latvia	6			5	5	1	1	0						
Lithuania	14	1	0	5	3	8	0	3						
Netherlands	5			4	4	1	0	1						
Norway	15			6	4	7	1	4			2	1		
Poland	1			1	0									
Portugal	18			8	8	9	0	9					1	1
Romania	12			2	2	10	1	9						
Slovakia	1					1	1							
Slovenia	3			1	1						2	2		
Spain	28			15	8	13	2	3						
Sweden	14			10	10	4	3	1						
United Kingdom	11			5	5	6	in process	1						
2019														
JANUARY														
Austria	17			6	6	10	10						1	1
Belgium	47			8	3	39	2	18						
Bulgaria	13			12	9	1	0	1						
Croatia	2												2	1
Cyprus	22			21	10	1	0	1						
Czech Republic	1			1	1									
Estonia	10			6	6	4	0	2						
Finland	1					1	0	1						
France	26			11	11	15	13	2						
Germany	34			15	15	19	5	14						
Greece	30			19	8	8	0	4	3	0				
Hungary	2					2	2							
Italy	6			3	3	1	0	1			2	1		
Latvia	6			6	6									
Lithuania	1			1	1									
Luxembourg	25			10	8	14	3	6					1	1
Malta	42			23	4	19	1	0						
Netherlands	12			8	8	4	2	2						
Norway	19			10	9	7	0	6					2	1
Poland	17			13	5	4	0	0						
Portugal	7			2	2	5	4	1						
Romania	13			11	6	2	1	1						
Slovakia	12			7	7	5	5							
Slovenia	14			9	9	4	0	4			1	1		
Spain	73			32	27	41	19	12						
Sweden	6			5	5	1	0	1						
United Kingdom	42	3	0	32	3	7	3	0						

MONTH / Country	TOTAL RECEIVED Seasonal viruses	A		H1N1pdm09		H3N2			B		B Victoria lineage		B Yamagata lineage	
		Number received	Number propagated[1]	Number received	Number propagated[1]	Number received	Number propagated[2]		Number received	Number propagated[1]	Number received	Number propagated[1]	Number received	Number propagated[1]
FEBRUARY														
Austria	5			4	4	1	1	0						
Bulgaria	42			23	22	19	13	9						
Cyprus	15			14	13	1	0	1						
Czech Republic	10			10	10									
Denmark	6			3	3	3	0	3						
Estonia	8			6	4	2	1	1						
Finland	4			4	4									
Germany	26			9	9	17	9	8						
Greece	17			11	10	5	1	4					1	1
Ireland	7			3	3	3	2	1					1	1
Italy	12			4	4	8	3	5						
Latvia	7			1	1	6	5	1						
Malta	8			5	2	3	0	1						
Poland	28	1	0	22	7	5	0	3						
Portugal	13			6	6	7	6	1						
Slovakia	13			10	10	3	3							
Slovenia	7			3	3	3	1	2			1	1		
Sweden	5			1	1	2	2				1	1	1	1
United Kingdom	14			4	4	10	10							
MARCH														
Austria	2												2	2
Bulgaria	1			1	1									
Cyprus	1					1	0	0						
Czech Republic	2					2	1	1						
Denmark	16			7	7	9	1	8						
Estonia	7			5	5	2	0	2						
Finland	7			2	2	5	2	3						
France	9			4	4	4	3	1					1	1
Germany	23			7	7	16	12	4						
Greece	15			8	3	6	1	4					1	1
Iceland	7			4	4	3	2	1						
Ireland	17			5	5	11	6	4			1	1		
Italy	15			6	6	9	8							
Latvia	2			1	1	1	1	0						
Norway	4					1	0	1			1	1	2	2
Poland	7			7	5									
Portugal	5			3	3	2	1	1						
Slovakia	4			2	2	2	2							
Slovenia	8			4	4	3	0	3			1	1		
Sweden	5			2	2	2	0	2			1	1		
United Kingdom	20			13	2	5	0				2	2		
APRIL														
Cyprus	1			1	1									
Czech Republic	2					2	1	1						
Denmark	1			1	1									
Finland	6			2	2	4	3	1						
France	15			3	3	12	7	5						
Iceland	7			1	1	4	1	3			2	2		
Ireland	3			1	0	2	1	1						
Norway	5					1	0	1			1	1	3	in process
Slovakia	1			1	1									
Slovenia	2			2	2									
United Kingdom	15					15	0							
MAY														
Finland	1					1	0	1						
France	1										1	1		
Iceland	7			2	2	5	1	4						
Norway	9					3	2	1			3	1	3	2
Portugal	1										1	0		
JUNE														
Iceland	2					2	1	1						
Norway	8			2	2	2	1	1			3	3	1	1
JULY														
Norway	11			4	4	3	1	1			4	4		
AUGUST														
Norway	7			3	in process	4	1	3						
30 Countries	1511	12	0	744	552	632	200	268	3	0	18	14	23	18
					49.2%		41.8%					1.2%		1.5%
					91.9%							2.9%		

1. Propagated to sufficient titre to perform HI assay (the totalled number does not include any from batches that are in process)
2. Propagated to sufficient titre to perform HI assay in the presence of 20nM oseltamivir (the totalled number does not include any from batches that are in process)

Numbers in red indicate viruses recovered but with insufficient HA titre to permit HI assay

Numbers highlighted in blue show the number of viruses subjected to HI assay for 'completed' sample sets. Under a 'sequence first' virus characterisation scheme: (i) sequencing only was possible for some clinical specimens that had been collected in lysis buffer; (ii) where sequencing failed, despite samples having good Ct values, virus propagation was attempted for only a few samples; and (iii) where multiple viruses shared the same HA sequence only a selection were propagated to allow assay by HI

One virus each from Denmark and Sweden were A(H1N2)pdm09 reassortants

As of 2019-09-27

Influenza A(H1N1)pdm09 virus analyses

Tables 3-1 to 3-6 show the results of haemagglutination inhibition (HI) assays of A(H1N1)pdm09 viruses performed with a panel of post-infection ferret antisera. Tables 3-1 and 3-2 are repeated from the July 2019 characterisation report but with genetic group data now included, while Tables 3-3 to 3-6 were generated since the July report. Test viruses in each table are sorted by date of collection and genetic group/subgroup (where known). A summary of the HI results for all (n = 85) test viruses in Tables 3-1 to 3-6, broken down by genetic group/subgroup, is shown in Table 3-7.

The proportion of A(H1N1)pdm09 test viruses that were antigenically indistinguishable from the A/Michigan/45/2015 northern hemisphere 2018–19 influenza season vaccine virus [3], being recognised at titres within twofold of the titre of the post-infection ferret antiserum with the homologous virus, was over 96% (Table 3-7). A similar proportion, over 94% being recognised at titres within twofold of the homologous titres, was seen with antiserum raised against the A/Brisbane/02/2018 northern hemisphere 2019–20 influenza season vaccine virus [1]. Slightly lower levels of recognition were observed with antisera raised against three other egg-propagated viruses, A/Slovenia/2903/2015, A/Switzerland/2656/2017 and A/Switzerland/3330/2017, with 73%, 85% and 89%, respectively, being recognised at titres within twofold of homologous titres, rising to 94%, 93% and 98% within fourfold of their respective homologous titres. Two additional antisera raised against more recently circulating egg-propagated viruses, A/Greece/144/2019 and A/Switzerland/4217/2019, were assessed against 30 test viruses (Table 3-1); both antisera recognised all test viruses at titres within fourfold of their respective homologous titres (Table 3-7).

Four antisera raised against cell culture-propagated viruses, A/Bayern/69/2009, A/Paris/1447/2017, A/Norway/3433/2018 and A/Ireland/84630/2018 recognised 95%, 91%, 98% and 80% of test viruses at titres within twofold of their respective homologous titres, rising to 100%, 97%, 98% and 97% at titres within fourfold. A fifth antiserum raised against cell culture-propagated A/Hong Kong/110/2019, a clade 6B.1A2 virus, recognised test viruses poorly at titres reduced at least sixteenfold compared to the homologous titre (Table 3-1).

The antiserum raised against cell culture-propagated A/Lviv/N6/2009 is an unusual virus/antiserum combination with A/Lviv/N6/2009 encoding **HA1** amino acid polymorphism of **G155G/E**, with E predominating, and **D222G** substitution. This antiserum recognised only 39% of test viruses at titres within twofold of the homologous titre, and 75% within fourfold (Table 3-7). Two viruses, A/England/137/2019 (Table 3-4) and A/Ireland/24488/2019 (Table 3-5), showed reduced recognition across the panel of antisera and contained **HA1** amino acid substitutions of **N156K** and **N156S**, respectively.

All test viruses for which HA gene sequencing had been completed fell into clade 6B.1, which is defined by the amino acid substitutions **S84N**, **S162N** (introducing a potential N-linked glycosylation site) and **I216T** in **HA1**, with all recently circulating viruses clustering in a genetic subclade designated as 6B.1A and defined by the HA1 amino acid substitutions **S74R**, **S164T** (which alters the glycosylation motif at residues 162 to 164) and **I295V**. A number of genetic subgroups defined by specific amino acid substitutions have emerged, but the great majority of viruses in the various subgroups had remained antigenically similar to A/Michigan/45/2015 as shown in earlier characterisation reports, as assessed with post-infection ferret antisera.

Figure 1 shows a phylogenetic tree for the HA genes of a selection of A(H1N1)pdm09 viruses, predominantly from the European Region with collection dates from 1 March 2019, many of which were sequenced at the Francis Crick Institute. Within subclade 6B.1A clusters of viruses (genetic groups) encoding a range of **HA1** amino acid substitutions have emerged, e.g. **T120A**, or **N260D** in combination with **N129D,** many with **T185I**, or **N260D** with **E235D** and **V193A** in **HA2**, or **N129D** with **A141E**, or **K302T** and **N169S** and **E179D** in **HA2**, or **L161I** and **I77M** in **HA2**. The HA of most recently circulating viruses carry the substitution **S183P** in **HA1**, although this is not retained in all genetic groups, and the phylogenetic tree is annotated with **HA1 S183P** substitution groups assigned for the February 2019 WHO Vaccine Consultation Meeting [1]; 6B.1A/183P-1 to -7, abbreviated to 6B.1A1 to 6B.1A7 in Figure 1. The location of vaccine viruses, A/Michigan/45/2015 [3] and the recently recommended A/Brisbane/02/2018 for the northern hemisphere 2019–20 influenza season [1], are indicated on the phylogeny (Figure 1).

Table 3-7 summarises the data in Tables 3-1 to 3-6 for viruses that had been sequenced at the time of preparing this report, by genetic groups 183P-2, -5, -6 and -7. Generally, test viruses reacted within fourfold of respective homologous titres with all antisera but for that raised against A/Lviv/N6/2009. Of the 85 test viruses 55 were in group 6B.1A5 (defined by **HA1 S183P** and **N260D** amino acid substitutions, with the great majority also having **N129D** and **T185I** substitutions) and all other groups were represented by less than 10 viruses. Despite this, the trend noted in the July report of group 6B.1A5 viruses showing lower proportions reacting within twofold of homologous titres with seven of the antisera in the panel was still seen (Table 3-7). While such HI studies conducted with post-infection ferret antisera indicated low levels of antigenic drift in A(H1N1)pdm09 viruses up to February 2019, panels of post-vaccination human antisera recognised viruses containing the HA1 substitution S183P less well and, based on these results, A/Brisbane/02/2018 was recommended as the A(H1N1)pdm09 vaccine component for the northern hemisphere 2019–20 [1] and southern hemisphere 2020 [2] influenza seasons.

Table 3-1. Antigenic analysis of A(H1N1)pdm09 viruses by HI

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre														
				Post-infection ferret antisera											NEW	NEW	NEW	
				A/Mich 45/15	A/Bayern 69/09	A/Lviv N6/09	A/Slov 2903/2015	A/Paris 1447/17	A/Swit 2656/17	A/Swit 3330/17	A/Norway 3433/18	A/Ire 84630/18	A/Bris 02/18	A/HK 110/19	A/Greece 144/19	A/Swit 4217/19
			Passage history	Egg	MDCK	MDCK	Egg	MDCK	Egg	Egg	MDCK	MDCK	Egg	MDCK	Egg	Egg
			Ferret number	F31/16[-1]	F09/15[-1]	F13/18[-1]	NIB F48/16[-1]	F03/18[-2]	F20/18[-1]	F23/18[-1]	F04/19[-1]	F08/19[-1]	F09/19[-1]	F28/19[-1]	F27/19[-1]	F22/19[-1]
			Genetic group	6B.1			6B.1	6B.1A	6B.1A	6B.1A5	6B.1A5	6B.1A6	6B.1A1	6B.1A2	6B.1A5	6B.1A5
REFERENCE VIRUSES																		
A/Michigan/45/2015		2015-09-07	E3/E3	1280	320	320	1280	2560	2560	1280	2560	2560	1280	40	2560	1280
A/Bayern/69/2009	G155E	2009-07-01	MDCK5/MDCK1	160	640	320	80	320	160	160	640	80	320	40	80	80
A/Lviv/N6/2009	G155E, D222G	2009-10-27	MDCK4/SIAT1/MDCK3	320	640	640	160	640	640	320	1280	320	640	40	80	160
A/Slovenia/2903/2015	clone 37	2015-10-26	E4/E2	1280	640	320	2560	2560	2560	1280	2560	2560	2560	40	1280	2560
A/Paris/1447/2017	6B.1	2017-10-20	MDCK1/MDCK3	1280	320	160	1280	2560	2560	1280	2560	2560	2560	80	2560	1280
A/Switzerland/2656/2017	6B.1A	2017-12-21	E5/E3	640	320	320	640	2560	1280	640	2560	640	640	40	640	640
A/Switzerland/3330/2017	6B.1A5 clone 35	2017-12-20	E6/E2	640	160	160	640	1280	640	1280	1280	1280	640	<	640	640
A/Norway/343/2018	6B.1A5	2018-10-30	MDCK3	640	160	80	640	1280	640	640	2560	1280	640	40	1280	1280
A/Ireland/8463O/2018	6B.1A6	2018-11-28	MDCK1/MDCK3	1280	320	160	1280	2560	2560	1280	2560	2560	1280	40	1280	2560
A/Brisbane/02/2018	6B.1A1	2018-01-04	E3/E1	2560	640	640	2560	5120	2560	1280	5120	5120	1280	160	2560	2560
A/Hong Kong/110/2019	6B.1A2	2019-01-01	MDCK1/MDCK2	160	160	80	<	40	160	80	320	80	640	1280	160	80
A/Greece/144/2019	6B.1A5	2019-01-14	E3	1280	320	160	1280	1280	1280	640	2560	1280	640	40	1280	1280
A/Switzerland/4217/2019	6B.1A5	2019-01-08	E4	1280	320	320	640	1280	1280	640	2560	1280	1280	80	640	1280
A/Switzerland/4217/2019	6B.1A5	2019-01-08	E4/E1	1280	320	320	640	1280	640	640	2560	1280	1280	80	640	1280
TEST VIRUSES																		
A/Bratislava/93/2019	6B.1A	2019-01-21	MDCKx/MDCK1	2560	320	320	1280	2560	5120	1280	5120	2560	2560	80	1280	2560
A/Padova/22/2019	6B.1A2	2019-02-20	MDCK4/MDCK1	1280	320	160	1280	1280	2560	640	1280	1280	1280	40	640	640
A/Kosice/422/2019	6B.1A2	2019-02-28	MDCKx/MDCK1	2560	640	320	2560	5120	2560	1280	2560	2560	2560	80	1280	2560
A/Banska Bystrica/115/2019	6B.1A5	2019-01-15	MDCKx/MDCK1	1280	640	320	1280	2560	1280	640	2560	2560	1280	80	1280	2560
A/Bratislava/76/2019	6B.1A5	2019-01-18	MDCK1/MDCK1	640	160	160	640	640	2560	640	5120	2560	1280	40	1280	1280
A/Trnava/85/2019	6B.1A5	2019-01-22	MDCK1/MDCK1	1280	320	160	640	1280	2560	1280	2560	1280	1280	40	1280	1280
A/Trencin/124/2019	6B.1A5	2019-01-28	MDCKx/MDCK1	1280	320	160	640	1280	2560	1280	5120	2560	1280	40	1280	1280
A/Malacky/145/2019	6B.1A5	2019-02-01	MDCKx/MDCK1	1280	640	640	1280	1280	2560	2560	5120	2560	2560	80	1280	1280
A/Lubica/183/2019	6B.1A5	2019-02-05	MDCKx/MDCK1	1280	320	320	1280	1280	2560	640	5120	2560	1280	80	1280	1280
A/Nitra/197/2019	6B.1A5	2019-02-08	MDCKx/MDCK1	1280	320	320	640	1280	2560	640	2560	2560	1280	80	1280	1280
A/Bojnice/225/2019	6B.1A5	2019-02-11	MDCKx/MDCK1	640	160	160	640	1280	2560	640	2560	1280	1280	40	640	1280
A/Bratislava/216/2019	6B.1A5	2019-02-11	MDCKx/MDCK1	1280	320	160	1280	1280	1280	640	2560	1280	1280	80	1280	2560
A/Piestany/267/2019	6B.1A5	2019-02-12	MDCKx/MDCK1	1280	320	320	1280	1280	1280	640	2560	2560	1280	80	1280	1280
A/Senica/305/2019	6B.1A5	2019-02-18	MDCKx/MDCK1	640	160	80	320	640	640	320	1280	640	640	40	640	2560
A/Torino/617/2019	6B.1A5	2019-02-19	MDCK4/MDCK1	640	160	80	640	1280	640	320	1280	640	640	<	640	640
A/Friuli Venezia Giulia/184/2019	6B.1A5	2019-02-21	MDCK2/MDCK1	1280	640	640	1280	2560	1280	640	2560	2560	1280	80	1280	1280
A/Padova/26/2019	6B.1A5	2019-02-25	MDCK3/MDCK1	640	320	160	640	1280	640	320	2560	1280	640	40	640	640
A/Galanta/387/2019	6B.1A5	2019-02-27	MDCKx/MDCK1	1280	320	320	1280	2560	1280	1280	2560	1280	1280	80	1280	1280
A/Torino/779/2019	6B.1A5	2019-03-06	MDCK4/MDCK1	2560	640	320	1280	2560	1280	640	2560	2560	1280	80	1280	1280
A/Palermo/23/2019	6B.1A5	2019-03-08	MDCK5/MDCK1	1280	640	160	1280	1280	1280	640	1280	2560	1280	80	1280	2560
A/Palermo/26/2019	6B.1A5	2019-03-12	MDCK3/MDCK1	1280	320	320	640	1280	1280	640	1280	1280	1280	80	1280	1280
A/Parma/370/2019	6B.1A5	2019-03-12	MDCK4/MDCK1	1280	320	320	640	1280	640	640	1280	1280	640	40	1280	640
A/Prievidza/518/2019	6B.1A5	2019-03-25	MDCKx/MDCK1	2560	640	640	1280	2560	2560	1280	2560	2560	1280	80	1280	2560
A/Trnava/429/2019	6B.1A6	2019-03-04	MDCKx/MDCK1	5120	640	320	2560	5120	5120	2560	5120	5120	2560	80	2560	2560
A/Parma/348/2019	6B.1A6	2019-03-06	MDCK2/MDCK1	2560	1280	640	2560	5120	2560	1280	2560	2560	2560	80	2560	2560
A/Trnava/535/2019	6B.1A6	2019-04-10	MDCKx/MDCK1	1280	640	160	1280	2560	2560	1280	2560	2560	1280	40	1280	1280
A/Piestany/80/2019	6B.1A7	2019-01-15	MDCK1/MDCK1	1280	320	160	1280	2560	1280	640	2560	2560	1280	40	1280	1280
A/Poprad/134/2019	6B.1A7	2019-01-29	MDCKx/MDCK1	1280	320	160	1280	2560	2560	1280	2560	2560	2560	80	1280	2560
A/Dunajska Streda/243/2019	6B.1A7	2019-02-12	MDCKx/MDCK1	1280	320	160	640	1280	1280	640	2560	2560	1280	40	640	2560
A/Torino/778/2019	6B.1A7	2019-03-06	MDCK4/MDCK1	640	320	160	640	1280	640	320	160	1280	640	40	320	640

Vaccine NH 2018-19 SH 2019

Vaccine NH 2019-20

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-2. Antigenic analysis of A(H1N1)pdm09 viruses by HI

Viruses	Other information	Passage history / Ferret number / Genetic group	Collection date	Passage history	Haemagglutination inhibition titre – Post-infection ferret antisera									
					A/Mich 45/15	A/Bayern 69/09	A/Lviv N6/09	A/Slov 2903/2015	A/Paris 1447/17	A/Swit 2656/17	A/Swit 3330/17	A/Norway 3433/18	A/Ire 84630/18	A/Bris 02/18
		Passage history			Egg	MDCK	MDCK	Egg	MDCK	Egg	Egg	MDCK	MDCK	Egg
		Ferret number			F31/16[*1]	F09/15[*1]	F13/18[*1]	NIB F48/16[*1]	F03/18[*2]	F20/18[*1]	F23/18[*1]	F04/19[*1]	F08/19[*1]	F09/19[*1]
		Genetic group			6B.1			6B.1	6B.1A	6B.1A	6B.1A5	6B.1A5	6B.1A6	6B.1A1
REFERENCE VIRUSES														
A/Michigan/45/2015		6B.1	2015-09-07	E3/E3	640	160	160	640	1280	640	320	640	640	640
A/Bayern/69/2009	G155E		2009-07-01	MDCK5/MDCK1	80	320	320	40	160	160	80	320	40	160
A/Lviv/N6/2009	G155E, D222G		2009-10-27	MDCK4/SIAT1/MDCK3	160	640	640	80	320	320	160	640	160	320
A/Slovenia/2903/2015	clone 37	6B.1	2015-10-26	E4/E2	1280	640	320	1280	2560	2560	1280	2560	1280	2560
A/Paris/1447/2017		6B.1A	2017-10-20	MDCK1/MDCK3	640	320	80	640	1280	1280	640	1280	1280	1280
A/Switzerland/2656/2017		6B.1A	2017-12-21	E5/E2	640	320	320	640	640	1280	640	2560	640	640
A/Switzerland/3330/2017	clone 35	6B.1A5	2017-12-20	E6/E2	640	160	160	640	1280	640	640	1280	640	640
A/Norway/3433/2018		6B.1A5	2018-10-30	MDCK4/SIAT1/MDCK3	320	80	40	640	640	320	320	640	640	320
A/Ireland/84630/2018		6B.1A6	2018-11-28	MDCK1/MDCK3	1280	320	320	1280	2560	2560	640	2560	2560	1280
A/Brisbane/02/2018		6B.1A1	2018-01-04	E3/E1	640	320	160	1280	1280	1280	640	1280	1280	640
TEST VIRUSES														
A/Estonia/118748/2019		6B.1A	2019-01-16	SIAT1/MDCK1	640	160	80	640	640	640	320	1280	640	640
A/Estonia/118882/2019		6B.1A	2019-01-23	SIAT2/MDCK1	1280	320	160	1280	2560	1280	1280	2560	1280	1280
A/Estonia/119176/2019		6B.1A	2019-02-06	MDCK1	1280	320	320	1280	1280	2560	1280	2560	1280	640
A/Estonia/120012/2019		6B.1A	2019-03-18	SIAT2/MDCK2	1280	320	160	1280	1280	2560	640	2560	1280	1280
A/Estonia/120077/2019		6B.1A	2019-03-20	SIAT2/MDCK1	640	160	80	640	1280	640	640	1280	640	640
A/Estonia/118723/2019		6B.1A5	2019-01-16	SIAT1/MDCK1	640	320	320	640	1280	1280	640	1280	640	640
A/Estonia/118840/2019		6B.1A5	2019-01-21	SIAT2/MDCK1	320	160	80	640	640	640	320	1280	640	320
A/Estonia/118896/2019		6B.1A5	2019-01-23	SIAT2/MDCK1	640	320	320	1280	1280	640	640	2560	1280	640
A/Czech Republic/1250/2019		6B.1A5	2019-01-30	MDCK3/MDCK1	1280	320	160	640	1280	640	640	5120	1280	640
A/Czech Republic/761/2019		6B.1A5	2019-02-04	MDCK3/MDCK1	640	160	80	320	640	320	320	2560	640	640
A/Estonia/119338/2019		6B.1A5	2019-02-11	SIAT2/MDCK1	1280	640	640	1280	2560	2560	1280	2560	2560	2560
A/Czech Republic/1254/2019		6B.1A5	2019-02-11	MDCK3/MDCK1	1280	320	160	640	1280	1280	640	2560	1280	1280
A/Czech Republic/1253/2019		6B.1A5	2019-02-11	MDCK3/MDCK1	640	160	40	320	640	320	320	1280	640	320
A/Czech Republic/1255/2019		6B.1A5	2019-02-13	MDCK3/MDCK1	640	160	80	640	640	640	320	2560	640	640
A/Czech Republic/1257/2019		6B.1A5	2019-02-14	MDCK3/MDCK1	640	160	160	640	1280	640	320	1280	640	640
A/Czech Republic/1256/2019		6B.1A5	2019-02-14	MDCK3/MDCK1	1280	640	640	1280	2560	1280	640	5120	2560	1280
A/Czech Republic/1258/2019		6B.1A5	2019-02-17	MDCK3/MDCK1	640	160	160	640	1280	640	320	1280	640	640
A/Estonia/119487/2019		6B.1A5	2019-02-18	SIAT2/SIAT1	640	320	320	640	1280	1280	640	2560	1280	640
A/Estonia/119483/2019		6B.1A5	2019-02-19	SIAT2/SIAT1	640	320	160	640	1280	640	640	2560	1280	640
A/Czech Republic/1259/2019		6B.1A5	2019-02-21	MDCK3/MDCK1	640	160	80	640	640	640	320	1280	640	640
A/Czech Republic/1262/2019		6B.1A5	2019-02-26	MDCK3/MDCK1	640	320	160	1280	1280	640	1280	2560	1280	640
A/Czech Republic/1261/2019		6B.1A5	2019-02-27	MDCK3/MDCK1	640	160	40	640	1280	640	640	1280	640	640
A/Estonia/119738/2019		6B.1A5	2019-03-04	SIAT2/MDCK1	1280	640	320	1280	2560	2560	640	2560	1280	1280
A/Estonia/119976/2019		6B.1A5	2019-03-18	SIAT2/SIAT1	640	160	80	640	1280	640	320	1280	640	640
A/Estonia/120189/2019		6B.1A5	2019-03-27	SIAT2/SIAT1	1280	640	320	1280	1280	1280	640	2560	1280	640
					Vaccine NH 2018-19 SH 2019									Vaccine NH 2019-20

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-3. Antigenic analysis of A(H1N1)pdm09 viruses by HI

Viruses	Other information	Passage history / Ferret number / Genetic group	Collection date	Passage history	Haemagglutination inhibition titre: Post-infection ferret antisera									
					A/Mich 45/15 Egg F31/16[*1] 6B.1	A/Bayern 69/09 MDCK F09/15[*1]	A/Lviv N6/09 MDCK F13/18[*1]	A/Slov 2903/2015 Egg NIB F48/16[*1] 6B.1	A/Paris 1447/17 MDCK F03/18[*2] 6B.1A	A/Swit 2656/17 Egg F20/18[*1] 6B.1A	A/Swit 3330/17 Egg F23/18[*1] 6B.1A5	A/Norway 3433/18 MDCK F04/19[*1] 6B.1A5	A/Ire 84630/18 MDCK F08/19[*1] 6B.1A6	A/Bris 02/18 Egg F09/19[*1] 6B.1A1
REFERENCE VIRUSES														
A/Michigan/45/2015		6B.1	2015-09-07	E3/E4	640	320	320	1280	1280	1280	640	1280	640	640
A/Bayern/69/2009	G155E		2009-07-01	MDCK5/MDCK1	80	320	160	40	160	80	80	320	40	80
A/Lviv/N6/2009	G155E, D222G		2009-10-27	MDCK4/SIAT1/MDCK3	160	320	640	80	320	320	160	640	80	160
A/Slovenia/2903/2015	clone 37	6B.1	2015-10-26	E4/E2	640	320	160	1280	2560	2560	1280	2560	1280	1280
A/Paris/1447/2017		6B.1A	2017-10-20	MDCK1/MDCK3	640	160	80	640	1280	1280	640	1280	640	640
A/Switzerland/2656/2017		6B.1A	2017-12-21	E5/E2	1280	640	640	1280	1280	2560	1280	2560	2560	1280
A/Switzerland/3330/2017	clone 35	6B.1A5	2017-12-20	E6/E2	320	160	160	640	1280	640	640	1280	640	320
A/Norway/3433/2018		6B.1A5	2018-10-30	MDCK4	320	80	<	320	640	320	320	640	320	320
A/Ireland/84630/2018		6B.1A6	2018-11-28	MDCK1/MDCK3	1280	320	160	1280	2560	2560	640	2560	1280	1280
A/Brisbane/02/2018		6B.1A1	2018-01-04	E3/E1	640	320	160	640	1280	1280	640	1280	1280	640
TEST VIRUSES														
A/Bretagne/1721/2019		6B.1A5	2019-03-18	MDCK1/MDCK1	160	160	80	80	160	320	160	320	40	160
A/Paris/1772/2019		6B.1A5	2019-03-22	MDCK1/MDCK1	640	160	320	640	320	640	320	1280	640	320
A/Alsace/1787/2019		6B.1A5	2019-03-26	MDCK1/MDCK1	320	160	40	320	320	640	320	1280	640	640
A/Brest/2004/2019		6B.1A5	2019-04-14	MDCK1/MDCK1	640	160	160	640	640	640	320	1280	640	640
A/Pays de Loire/1751/2019		6B.1A7	2019-03-20	MDCK1/MDCK1	640	320	160	640	1280	1280	640	2560	1280	1280
A/Brest/2003/2019		6B.1A7	2019-04-13	MDCK1/MDCK1	1280	320	1280	1280	1280	1280	640	25630	2560	1280
A/Bretagne/1920/2019		6B.1A7	2019-04-13	MDCK1/MDCK1	640	160	80	1280	640	1280	640	1280	1280	640
					Vaccine NH 2018-19 SH 2019								Vaccine NH 2019-20	

*Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-4. Antigenic analysis of A(H1N1)pdm09 viruses by HI

Viruses	Other information	Passage history / Ferret number / Genetic group	Collection date	Passage history	Haemagglutination inhibition titre: Post-infection ferret antisera									
					A/Mich 45/15 Egg F31/16*1 6B.1	A/Bayern 69/09 MDCK F09/15*1	A/Lviv N6/09 MDCK F13/18*1	A/Slov 2903/2015 Egg NIB F48/16*1 6B.1	A/Paris 1447/17 MDCK F03/18*2 6B.1A	A/Swit 2656/17 Egg F20/18*1 6B.1A	A/Swit 3330/17 Egg F23/18*1 6B.1A5	A/Norway 3433/18 MDCK F04/19*1 6B.1A5	A/Ire 84630/18 MDCK F08/19*1 6B.1A6	A/Bris 02/18 Egg F09/19*1 6B.1A1
REFERENCE VIRUSES														
A/Michigan/45/2015		6B.1	2015-09-07	E3/E4	640	320	320	1280	2560	1280	640	2560	1280	1280
A/Bayern/69/2009	G155E		2009-07-01	MDCK5/MDCK1	80	320	320	40	160	160	80	320	40	80
A/Lviv/N6/2009	G155E, D222G		2009-10-27	MDCK4/SIAT1/MDCK3	320	640	1280	160	640	320	320	1280	160	320
A/Slovenia/2903/2015	clone 37	6B.1	2015-10-26	E4/E2	1280	320	160	1280	1280	1280	640	1280	640	640
A/Paris/1447/2017		6B.1A	2017-10-20	MDCK1/MDCK3	640	160	80	640	1280	640	640	1280	640	320
A/Switzerland/2656/2017		6B.1A	2017-12-21	E5/E2	2560	640	1280	2560	2560	2560	1280	2560	2560	1280
A/Switzerland/3330/2017	clone 35	6B.1A5	2017-12-20	E6/E2	640	160	160	640	1280	640	640	1280	640	640
A/Norway/3433/2018		6B.1A5	2018-10-30	MDCK4	320	80	40	320	320	320	320	1280	320	160
A/Ireland/84630/2018		6B.1A6	2018-11-28	MDCK1/MDCK3	1280	160	160	1280	1280	1280	640	2560	1280	640
A/Brisbane/02/2018		6B.1A1	2018-01-04	E3/E1	1280	320	320	1280	2560	1280	1280	2560	1280	1280
TEST VIRUSES														
A/England/137/2019	N156K	6B.1A2	2019-01-14	SIAT1/MDCK1	80	160	40	40	40	160	80	160	40	80
A/England/228/2019		6B.1A5	2019-02-13	SIAT2/MDCK1	640	320	160	640	1280	1280	640	2560	1280	640
A/England/158/2019		6B.1A5	2019-02-23	SIAT1/MDCK1	1280	320	160	1280	1280	1280	640	2560	1280	640
A/England/246/2019		6B.1A5	2019-03-15	SIAT1/MDCK1	640	160	160	640	1280	640	320	1280	640	640
A/England/190/2019		6B.1A6	2019-02-10	SIAT1/MDCK1	1280	320	80	1280	2560	1280	1280	2560	1280	1280
A/England/214/2019		6B.1A6	2019-02-18	SIAT1/MDCK1	1280	640	160	1280	2560	2560	640	2560	1280	1280
A/England/234/2019		6B.1A7	2019-03-09	SIAT1/MDCK1	1280	320	160	1280	2560	1280	640	2560	1280	1280
					Vaccine NH 2018-19 SH 2019									Vaccine NH 2019-20

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-5. Antigenic analysis of A(H1N1)pdm09 viruses by HI

Viruses	Other information	Passage history / Ferret number / Genetic group	Collection date	Passage history	Haemagglutination inhibition titre – Post-infection ferret antisera: A/Mich 45/15 Egg F31/16*1 6B.1	A/Bayern 69/09 MDCK F09/15*1	A/Lviv N6/09 MDCK F13/18*1	A/Slov 2903/2015 Egg NIB F48/16*1 6B.1	A/Paris 1447/17 MDCK F03/18*2 6B.1A	A/Swit 2656/17 Egg F20/18*1 6B.1A	A/Swit 3330/17 Egg F23/18*1 6B.1A5	A/Norway 3433/18 MDCK F04/19*1 6B.1A5	A/Ire 84630/18 MDCK F08/19*1 6B.1A6	A/Bris 02/18 Egg F09/19*1 6B.1A1
REFERENCE VIRUSES														
A/Michigan/45/2015		6B.1	2015-09-07	E3/E4	1280	320	320	1280	2560	1280	1280	1280	1280	1280
A/Bayern/69/2009	G155E		2009-07-01	MDCK5/MDCK1	80	160	160	< 160	160	80	80	160	40	80
A/Lviv/N6/2009	G155E, D222G		2009-10-27	MDCK4/SIAT1/MDCK3	320	640	640	160	640	320	320	640	160	320
A/Slovenia/2903/2015	clone 37	6B.1	2015-10-26	E4/E2	2560	640	640	2560	1280	2560	1280	1280	1280	1280
A/Paris/1447/2017		6B.1A	2017-10-20	MDCK1/MDCK3	640	160	40	640	1280	640	320	640	640	320
A/Switzerland/2656/2017		6B.1A	2017-12-21	E5/E2	640	320	320	1280	2560	1280	640	1280	640	640
A/Switzerland/3330/2017	clone 35	6B.1A5	2017-12-20	E6/E2	640	160	160	640	1280	640	640	640	640	320
A/Norway/3433/2018		6B.1A5	2018-10-30	MDCK4	320	80	< 320	320	320	320	320	640	320	320
A/Ireland/84630/2018		6B.1A6	2018-11-28	MDCK1/MDCK3	1280	160	160	1280	1280	1280	640	1280	640	320
A/Brisbane/02/2018		6B.1A1	2018-01-04	E3/E1	1280	320	320	1280	2560	1280	1280	2560	1280	1280
TEST VIRUSES														
A/Ireland/24181/2019		6B.1A2	2019-03-04	MDCK1/MDCK1	640	160	160	1280	640	1280	640	1280	640	640
A/Ireland/22361/2019		6B.1A5	2019-02-25	MDCK1/MDCK1	1280	320	160	1280	640	1280	640	1280	1280	640
A/Ireland/23159/2019		6B.1A5	2019-02-27	MDCK1/MDCK1	640	160	80	320	320	640	320	1280	640	320
A/Ireland/24488/2019	N156S	6B.1A5	2019-03-05	MDCK1/MDCK1	80	80	<	<	<	80	40	320	<	40
A/Ireland/26203/2019		6B.1A5	2019-03-07	MDCK1/MDCK1	640	320	160	640	1280	640	320	1280	640	640
A/Ireland/29434/2019		6B.1A5	2019-03-22	MDCK1/MDCK1	640	320	160	640	1280	640	320	1280	640	640
A/Ireland/22715/2019		6B.1A7	2019-02-26	MDCK1/MDCK1	1280	320	160	1280	1280	1280	640	1280	1280	640
A/Ireland/23810/2019		6B.1A7	2019-03-01	MDCK2/MDCK1	640	160	80	640	640	640	320	1280	640	640
					Vaccine NH 2018-19 SH 2019									Vaccine NH 2019-20

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-6. Antigenic analysis of A(H1N1)pdm09 viruses by HI – Summary all test viruses

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre										
				Post-infection ferret antisera										
	Passage history			A/Mich 45/15	A/Bayern 69/09	A/Lviv N6/09	A/Slov 2903/2015	A/Paris 1447/17	A/Swit 2656/17	A/Swit 3330/17	A/Norway 3433/18	A/Ire 84630/18	A/Bris 02/18
				Egg	MDCK	MDCK	Egg	MDCK	Egg	Egg	MDCK	MDCK	Egg
	Ferret number			F31/16*1	F09/15*1	F13/18*1	NIB F48/16*1	F03/18*2	F20/18*1	F23/18*1	F04/19*1	F08/19*1	F09/19*1
	Genetic group			6B.1			6B.1	6B.1A	6B.1A	6B.1A5	6B.1A5	6B.1A6	6B.1A1
REFERENCE VIRUSES													
A/Michigan/45/2015	6B.1	2015-09-07	E3/E4	1280	320	320	2560	2560	2560	1280	2560	1280	1280
A/Bayern/69/2009	G155E	2009-07-01	MDCK5/MDCK1	80	320	160	40	160	160	80	320	40	80
A/Lviv/N6/2009	G155E, D222G	2009-10-27	MDCK4/SIAT1/MDCK3	320	640	640	160	640	320	320	1280	160	320
A/Slovenia/2903/2015	clone 37 6B.1	2015-10-26	E4/E2	1280	320	320	1280	1280	1280	1280	2560	1280	640
A/Paris/1447/2017	6B.1A	2017-10-20	MDCK1/MDCK3	640	160	80	640	1280	1280	640	1280	640	640
A/Switzerland/2656/2017	6B.1A	2017-12-21	E5/E2	1280	640	640	2560	2560	2560	1280	2560	2560	1280
A/Switzerland/3330/2017	clone 35 6B.1A5	2017-12-20	E6/E2	640	320	160	640	1280	1280	320	1280	1280	640
A/Norway/3433/2018	6B.1A5	2018-10-30	MDCK4	320	80	40	320	320	320	320	1280	320	320
A/Ireland/84630/2018	6B.1A6	2018-11-28	MDCK1/MDCK3	1280	320	160	1280	2560	1280	1280	2560	1280	1280
A/Brisbane/02/2018	6B.1A1	2018-01-04	E3/E1	1280	320	320	1280	2560	1280	1280	2560	1280	1280
TEST VIRUSES													
A/Norway/2133/2019	6B.1A5	2019-06-03	MDCK1	1280	320	320	1280	1280	1280	640	2560	1280	640
A/Norway/2148/2019	6B.1A5	2019-06-19	MDCK1	640	320	160	1280	1280	1280	640	2560	1280	640
A/Norway/2200/2019	6B.1A5	2019-07-17	MDCK1/MDCK1	640	160	80	640	640	320	320	1280	640	640
A/Norway/2193/2019	6B.1A5	2019-07-18	MDCK1/MDCK1	640	160	80	320	640	320	640	1280	640	640
A/Norway/2196/2019	6B.1A5	2019-07-19	MDCK1/MDCK1	640	160	80	640	640	320	320	1280	640	320
A/Norway/2223/2019	6B.1A5	2019-07-26	MDCK1/MDCK1	640	160	160	640	1280	640	640	2560	1280	640
A/Norway/2231/2019	6B.1A5	2019-08-15	MDCK1	1280	320	80	1280	1280	1280	1280	2560	2560	1280
A/Norway/2228/2019	6B.1A5	2019-08-15	MDCK1	2560	640	160	2560	2560	2560	1280	5120	2560	1280
							Vaccine NH 2018-19 SH 2019						Vaccine NH 2019-20

*Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used)
1 < = <40; 2 < = <80
Sequences in phylogenetic trees

Table 3-7. Antigenic analysis of A(H1N1)pdm09 viruses by HI – Summary by test virus genetic group

Viruses	Other information		Haemagglutination inhibition titre: Post-infection ferret antisera										NEW	NEW	NEW
		Passage history	A/Mich 45/15 Egg	A/Bayern 69/09 MDCK	A/Lviv N6/09 MDCK	A/Slov 2903/2015 Egg	A/Paris 1447/17 MDCK	A/Swit 2656/17 Egg	A/Swit 3330/17 Egg	A/Norway 3433/18 MDCK	A/Ire 84630/18 MDCK	A/Bris 02/18 Egg	A/HK 110/19 MDCK	A/Greece 144/19 Egg	A/Swit 4217/19 Egg
		Ferret number	F31/16[*1]	F09/15[*1]	F13/18[*1]	NIB F48/16[*1]	F03/18[*2]	F20/18[*1]	F23/18[*1]	F04/19[*1]	F08/19[*1]	F09/19[*1]	F28/19[*1]	F27/19[*1]	F22/19[*1]
		Genetic group	6B.1			6B.1	6B.1A	6B.1A	6B.1A5	6B.1A5	6B.1A6	6B.1A1	6B.1A2	6B.1A5	6B.1A5
REFERENCE VIRUSES															
A/Michigan/45/2015		6B.1	1280	320	320	1280	2560	2560	1280	2560	2560	1280	40	2560	1280
A/Bayern/69/2009	G155E		160	640	320	80	320	160	160	640	80	320	40	80	80
A/Lviv/N6/2009	G155E, D222G		320	640	640	160	640	640	320	1280	320	640	40	80	160
A/Slovenia/2903/2015	clone 37	6B.1	1280	640	320	2560	2560	2560	1280	2560	2560	2560	40	1280	2560
A/Paris/1447/2017		6B.1A	1280	320	160	1280	2560	2560	1280	5120	2560	2560	80	2560	1280
A/Switzerland/2656/2017		6B.1A	640	320	320	640	640	1280	640	2560	640	640	40	640	640
A/Switzerland/3330/2017	clone 35	6B.1A5	640	160	160	640	1280	640	1280	1280	1280	640	<	640	640
A/Norway/3433/2018		6B.1A5	640	160	80	640	1280	640	640	2560	1280	640	40	1280	1280
A/Ireland/84630/2018		6B.1A6	1280	320	160	1280	2560	2560	1280	2560	2560	1280	40	1280	2560
A/Brisbane/02/2018		6B.1A1	2560	640	640	2560	5120	2560	2560	5120	5120	1280	160	2560	2560
A/Hong Kong/110/2019		6B.1A2	160	160	80	<	40	160	80	320	80	80	1280	160	80
A/Greece/144/2019		6B.1A5	1280	320	160	1280	1280	1280	640	2560	1280	640	40	1280	1280
A/Switzerland/4217/2019		6B.1A5	1280	320	320	640	1280	1280	640	2560	1280	1280	80	640	1280
A/Switzerland/4217/2019		6B.1A5	1280	320	320	640	1280	640	640	2560	1280	1280	80	640	1280
TEST VIRUSES															
Genetic group	*No tested*	*No with*											Used in 1 assay: 30 viruses tested		
All viruses	85	Titre reduced ≤2-fold	82	81	33	62	77	72	76	83	68	80		29	30
		%	*96.5*	*95.3*	*38.8*	*72.9*	*90.6*	*84.7*	*89.4*	*97.6*	*80.0*	*94.1*		*96.7*	*100.0*
		Titre reduced =4-fold	1	4	31	18	5	7	7		14	3		1	
		%	*1.1*	*4.7*	*36.5*	*21.2*	*5.9*	*8.2*	*8.2*		*16.5*	*3.5*		*3.3*	
		Titre reduced ≥8-fold	2		21	5	3	6	2	2	3	2	30		
		%	*2.4*		*24.7*	*5.9*	*3.5*	*7.1*	*2.4*	*2.4*	*3.5*	*2.4*	*100.0*		
6B.1A	6	Titre reduced ≤2-fold	6	6	2	6	6	6	6	6	4	6		1	1
		Titre reduced =4-fold			2						2				
		Titre reduced ≥8-fold			2								1		
6B.1A2	3	Titre reduced ≤2-fold	2	3	1	2	2	2	2	2	2	2		2	2
		Titre reduced =4-fold			1										
		Titre reduced ≥8-fold	1		1	1	1	1	1	1	1	1	2		
6B.1A5	55	Titre reduced ≤2-fold	54	51	15	40	50	44	49	55	42	53		20	20
		%	*98.2*	*92.7*	*27.3*	*72.7*	*90.9*	*80.0*	*89.1*	*100.0*	*76.4*	*96.4*		*100.0*	*100.0*
		Titre reduced =4-fold	1	4	22	13	4	7	6		12	2			
		%	*1.8*	*7.3*	*40.0*	*23.6*	*7.3*	*12.7*	*10.9*		*21.8*	*3.6*			
		Titre reduced ≥8-fold			18	2	1	4			1		20		
		%			*32.7*	*3.7*	*1.8*	*7.3*			*1.8*		*100.0*		
6B.1A6	5	Titre reduced ≤2-fold	5	5	3	5	5	5	5	5	5	5		3	3
		Titre reduced =4-fold													
		Titre reduced ≥8-fold			2								3		
6B.1A7	8	Titre reduced ≤2-fold	8	8	5	6	8	8	7	7	8	8		3	4
		Titre reduced =4-fold			1	2			1					1	
		Titre reduced ≥8-fold			2					1			4		

Figure 1. Phylogenetic comparison of influenza A(H1N1)pdm09 HA genes



Influenza A(H3N2) virus analyses

As described in many previous reports[2], influenza A(H3N2) viruses have continued to be difficult to characterise antigenically by HI assay due to variable agglutination of red blood cells (RBCs) from guinea pigs, turkeys and humans, often with the loss of ability to agglutinate any of these RBCs. As was highlighted first in the November 2014 report[3], this is a particular problem for most viruses that fall in genetic clade 3C.2a.

Since the July 2019 characterisation report of the viruses recovered, based on positive neuraminidase activity, 37 retained sufficient HA activity to allow antigenic analysis by HI (Tables 4-2 to 4-2); the test virus results for both tables are summarised in Table 4-3. All but two test viruses were poorly recognised by the antiserum raised against the recently used vaccine virus, egg-propagated A/Singapore/INFIMH-16-0019/2016 (subclade 3C.2a1). This was also the case with antisera raised against other egg-propagated vaccine viruses, A/Switzerland/8060/2017 (subclade 3C.2a2) and A/Kansas/14/2017 (clade 3C.3a) – respectively, no (0%) and five (14%) test viruses were recognised at titres fourfold reduced compared to homologous titres.

Similarly, an antiserum raised against cell culture-propagated A/Bretagne/1413/2017 (subclade 3C.2a2) recognised only 1/37 (3%) test viruses at titres within fourfold of homologous titres, while antisera raised against two cell culture-propagated clade 3C.3a viruses, A/England/538/2018 and A/Kansas/14/2017, fared somewhat better recognising 76% and 65% of test viruses, respectively, at titres within fourfold of homologous titres. The two antisera raised against cell culture-propagated subgroup 3C.2a1b viruses, A/La Rioja/2202/2018 and A/Norway/3275/2018, for which no homologous titres are given due to the inability of these cell culture-propagated reference viruses to agglutinate RBCs, recognised 11 and 10 test viruses, respectively, at titres of ≥160. Antiserum raised against cell culture-propagated A/Hong Kong/5738/2014 (clade 3C.2a) recognised 89% of test viruses at titres within fourfold of homologous titres.

Overall, the HI data show poor recognition of test viruses by post-infection ferret antisera raised against egg-propagated vaccine/reference viruses. Further, for test viruses of known genetic clade/subclade the data shows: (i) poor cross-reactivity of antisera raised against a subclade 3C.2a2 virus, (ii) clade specificity of the antisera raised against cell culture-propagated clade 3C.3a viruses, A/England/538/2018 and A/Kansas/14/2017, and (iii) of the six antisera raised against cell culture-propagated viruses, the one raised against A/Hong Kong/5738/2014 (clade 3C.2a) gives the broadest cross-clade/subclade reactivity.

Viruses in clades 3C.2a and 3C.3a have been in circulation since the 2013–14 northern hemisphere influenza season, with clade 3C.2a viruses having been dominant since the 2014–15 influenza season, notably subclade 3C.2a2 viruses, though subgroup 3C.2a1b viruses have predominated over the course of the 2018–19 season, as shown for representative viruses with collection dates from 1 March 2019 (Figure 2). The HA gene sequences of viruses in both clades continue to diverge. Notably, clade 3C.3a viruses have evolved to carry **HA1** amino acid substitutions of **L3I, S91N**, **N144K** (loss of a N-linked glycosylation motif at residues 144-146), **F193S** and **K326R**, and **D160N** in **HA2**, compared with A/Stockholm/6/2014, and levels of detection since January 2019 have increased in a number of WHO European Region countries (Figure 2) and North America. New genetic groups have also emerged among the clade 3C.2a viruses, designated as subclades/subgroups. Amino acid substitutions that define these subclades/subgroups are:

- Clade 3C.2a: **L3I**, **N144S** (resulting in the loss of a potential glycosylation site), **F159Y**, **K160T** (in the majority of viruses, resulting in the gain of a potential glycosylation site) and **Q311H** in **HA1**, and **D160N** in **HA2**, e.g. A/Hong Kong/7295/2014 a cell culture-propagated surrogate for A/Hong Kong/4801/2014 (a former vaccine virus)
- Subclade 3C.2a1: those in clade 3C.2a plus: **N171K** in **HA1** and **I77V** and **G155E** in **HA2,** most also carry **N121K** in **HA1**, e.g. A/Singapore/INFIMH-16-0019/2016 (2018–19 northern hemisphere vaccine virus)
- Subgroup 3C.2a1a: those in subclade 3C.2a1 plus **T135K** in **HA1**, resulting in the loss of a potential glycosylation site, and also **G150E** in **HA2**, e.g. A/Greece/4/2017
- Subgroup 3C.2a1b: those in subclade 3C.2a1 plus **K92R** and **H311Q** in **HA1**, e.g. A/La Rioja/2202/2018, with many viruses in this subgroup carrying additional HA1 amino acid substitutions
- Subclade 3C.2a2: those in clade 3C.2a plus **T131K**, **R142K** and **R261Q** in **HA1**, e.g. A/Switzerland/8060/2017 (2019 southern hemisphere vaccine virus)
- Subclade 3C.2a3: those in clade 3C.2a plus **N121K** and **S144K** in **HA1**, e.g. A/Cote d'Ivoire/544/2016
- Subclade 3C.2a4: those in clade 3C.2a plus **N31S, D53N, R142G, S144R, N171K, I192T, Q197H** and **A304T** in **HA1** and **S113A** in **HA2**, e.g. A/Valladolid/182/2017

[2] For example, the September 2013 report: European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, September 2013. Stockholm: ECDC; 2014. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/influenza-virus-characterisation-sep-2013.pdf

[3] European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, November 2014. Stockholm: ECDC; 2014. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/ERLI-Net%20report%20November%202014.pdf

- Clade 3C.3a: **T128A** (resulting in the loss of a potential glycosylation site), **R142G** and **N145S** in **HA1** which defined clade 3C.3 plus **A138S**, **F159S** and **N225D** in **HA1**, many with **K326R**, e.g. A/England/538/2018.

Globally, the great majority of viruses with collection dates from 1 September 2018 have HA genes that continue to fall into genetic groups within clade 3C.2a, with those in subgroup 3C.2a1b having been more numerous than those in subclade 3C.2a2 for the period September 2018 to June 2019 (Figure 2). Notably, a significant number of the subgroup 3C.2a1b viruses have fallen in two recently emerged clusters; one defined by amino acid substitutions **T131K** in **HA1** with **V200I** in **HA2** and the other by **T128A** and **T135K** substitutions in **HA1** (both resulting in loss of potential glycosylation sequons). Further, as indicated above, numbers of clade 3C.3a virus detections have increased over the course of the 2018–19 season in a number of countries/regions.

The locations of A/Singapore/INFIMH-16-0019/2016 (3C.2a1), the A(H3N2) virus recommended for inclusion in vaccines for the northern hemisphere 2018–19 influenza season [3], A/Switzerland/8060/2017 (3C.2a2), the A(H3N2) virus recommended for inclusion in vaccines for the southern hemisphere 2019 influenza season [4], A/Kansas/14/2017, the A(H3N2) virus recommended for inclusion in vaccines for the northern hemisphere 2019–20 influenza season [1], and A/South Australia/34/2019, the A(H3N2) virus recommended for inclusion in vaccines for the southern hemisphere 2020 influenza season [2], are indicated in Figure 2.

Table 4-1. Antigenic analysis of A(H3N2) viruses by HI

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre								
				Post-infection ferret antisera								
	Passage history			A/HK 5738/14 MDCK	A/Bretagne 1413/17 SIAT	A/Singapore 0019/16 Egg 10^{-4}	A/La Rioja 2202/18 SIAT	A/Switz 8060/17 Egg	A/Eng 538/18 SIAT	A/Norway 3275/18 SIAT	NYMC X-327 A/Kansas/14 Egg	A/Kansas 14/17 SIAT
	Ferret number			St Judes F60/17 [-1]	F01/18 [+1]	F46/17 [+1]	F26/18 [+1]	F27/18 [+1]	F31/18 [-1]	F03/19 [+1]	F16/19 [-1]	F17/19 [+1]
	Genetic group			3C.2a	3C.2a2	3C.2a1	3C.2a1b	3C.2a2	3C.3a	3C.2a1b	3C.3a	3C.3a
REFERENCE VIRUSES												
A/Hong Kong/5738/2014	3C.2a	2014-04-30	MDCK1/MDCK2/SIAT1	160	160	320	160	320	640	320	320	160
A/Bretagne/1413/2017	3C.2a2	2017-10-09	MDCK1/SIAT5	160	640	160	80	640	320	160	160	80
A/Singapore/INFIMH-16-0019/2016	3C.2a1	2016-04-14	E5/E2	160	80	640	320	160	80	40	40	40
A/Switzerland/8060/2017 clone 57	3C.2a2	2017-12-12	E7/E1	160	1280	640	160	1280	80	80	40	80
A/England/538/2018	3C.3a	2018-02-26	MDCK1/SIAT3	<	<	40	<	40	320	<	160	320
NYMC X-327 (A/Kansas/14/17)	3C.3a	2017-12-14	Ex/E1	40	40	80	<	<	320	<	1280	640
A/Kansas/14/2017	3C.3a	2017-12-14	SIAT3/SIAT2	40	40	40	<	40	320	<	160	320
TEST VIRUSES												
A/Estonia/119303/2019	3C.2a1b	2019-02-11	SIAT2/SIAT2	80	<	40	320	40	40	160	40	40
A/Torino/780/2019	3C.2a1b	2019-03-01	SIAT1/SIAT1	40	<	<	80	<	<	80	<	<
A/Torino/544/2019	3C.2a1b	2019-03-06	SIAT4/SIAT2	80	40	40	160	40	80	160	40	<
A/Czech Republic/1031/2019	3C.2a1b	2019-03-10	SIAT1/SIAT1	<	<	<	80	<	<	80	<	<
A/Parma/379/2019	3C.2a1b	2019-03-18	SIAT3/SIAT2	40	<	80	80	40	40	80	40	40
A/Champagne Ardenne/1908/2019	3C.2a1b	2019-03-26	SIAT1	40	40	40	<	40	320	<	80	160
A/Nord Pas de Calais/1803/2019	3C.2a1b	2019-04-10	MDCK3/SIAT1	80	40	80	40	80	640	<	160	320
A/Palermo/20/2019	3C.2a1b	2019-05-31	SV/SIAT1	40	<	80	160	40	40	80	<	<
A/Parma/377/2019	3C.3a	2019-02-19	SIAT3/SIAT2	80	40	160	160	80	80	160	40	40
A/Parma/373/2019	3C.3a	2019-02-26	SIAT4/SIAT1	40	40	80	40	80	640	<	160	320
A/Parma/361/2019	3C.3a	2019-02-27	SIAT3/SIAT1	40	40	40	<	40	320	<	160	320
A/Palermo/13/2019	3C.3a	2019-03-05	SIAT3/SIAT1	40	40	40	<	40	320	<	80	160
A/Torino/771/2019	3C.3a	2019-03-05	SIAT3/SIAT2	40	40	40	<	40	320	<	160	160
A/Palermo/12/2019	3C.3a	2019-03-06	SIAT3/SIAT2	80	40	80	160	80	80	160	80	40
A/Parma/353/2019	3C.3a	2019-03-06	MDCK4/SIAT1	<	<	<	80	<	<	40	<	<
A/Czech Republic/1275/2019	3C.3a	2019-03-08	SIAT3/SIAT1	40	40	40	<	40	640	<	160	320
A/Brest/2002/2019	3C.3a	2019-03-11	SIAT2SIAT1	<	40	40	<	40	320	<	160	160
A/Brest/2001/2019	3C.3a	2019-03-15	SIAT2SIAT1	40	40	40	<	40	320	<	160	160
A/Bretagne/1913/2019	3C.3a	2019-03-26	MDCK2/SIAT1	80	40	80	160	40	40	160	<	<
A/Brest/1999/2019	3C.3a	2019-03-30	MDCK1/SIAT1	40	40	40	<	80	320	<	160	160
A/Picardie/1898/2019	3C.3a	2019-04-07	MDCK1/SIAT1	<	<	<	<	<	320	<	80	160
A/Brest/1998/2019	3C.3a	2019-04-08	MDCK1/SIAT1	40	40	80	40	80	320	<	160	320
A/Centre/1846/2019	3C.3a	2019-04-08	MDCK1/SIAT1	40	40	40	<	40	320	<	160	160
A/Basse Normandie/1798/2019	3C.3a	2019-04-10	MDCK2/SIAT1	80	80	80	160	160	80	160	<	<
						Vaccine SH 2018 NH 2018-19		Vaccine SH 2019			Vaccine NH 2019-20	

*Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used) [1] < = <40

Sequences in phylogenetic trees

Table 4-2. Antigenic analysis of A(H3N2) viruses by HI

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre								
				Post-infection ferret antisera								
	Passage history			A/HK 5738/14 MDCK	A/Bretagne 1413/17 SIAT	A/Singapore 0019/16 Egg 10^{-4}	A/La Rioja 2202/18 SIAT	A/Switz 8060/17 Egg	A/Eng 538/18 SIAT	A/Norway 3275/18 SIAT	NYMC X-327 A/Kansas/14 Egg	A/Kansas 14/17 SIAT
	Ferret number			St Judes F-60/17 [-1]	F01/18 [-1]	F46/17 [-1]	F26/18 [-1]	F27/18 [-1]	F31/18 [-1]	F03/19 [-1]	F16/19 [-1]	F17/19 [-1]
	Genetic group			3C.2a	3C.2a2	3C.2a1	3C.2a1b	3C.2a2	3C.3a	3C.2a1b	3C.3a	3C.3a
REFERENCE VIRUSES												
A/Hong Kong/5738/2014	3C.2a	2014-04-30	MDCK1/MDCK2/SIAT1	160	160	320	160	320	320	160	160	160
A/Bretagne/1413/2017	3C.2a2	2017-10-09	MDCK1/SIAT5	320	640	320	80	640	320	320	160	160
A/Singapore/INFIMH-16-0019/2016	3C.2a1	2016-04-14	E5/E2	160	80	1280	320	320	80	80	80	80
A/Switzerland/8060/2017 clone 57	3C.2a2	2017-12-12	E7/E1	160	1280	1280	160	2560	160	160	160	160
A/England/538/2018	3C.3a	2018-02-26	MDCK1/SIAT3	40	40	80	<	40	640	<	320	320
NYMC X-327 (A/Kansas/14/17)	3C.3a	2017-12-14	E×/E1	40	40	160	<	40	320	<	1280	320
A/Kansas/14/2017	3C.3a	2017-12-14	SIAT3/SIAT2	80	80	80	40	80	640	<	320	320
TEST VIRUSES												
A/England/93/2019	3C.2a1b	2019-01-31	MDCK2/SIAT1/SIAT1	160	80	160	160	160	160	160	40	80
A/England/95/2019	3C.2a1b	2019-02-04	SIAT3/SIAT1	40	40	40	80	40	40	160	<	40
A/England/99/2019	3C.2a1b	2019-02-07	MDCK2/SIAT1/SIAT1	80	40	160	160	80	160	160	80	640
A/England/102/2019	3C.2a1b	2019-02-12	SIAT2/SIAT1	80	40	160	160	80	80	80	80	40
A/England/eWIsYW9mYWxlaQ/2019	3C.2a2	2019-02-08	MDCK1/SIAT1/SIAT1	160	320	320	160	320	320	160	160	320
A/England/fmhwY2NxZm9pZg/2018	3C.2a3	2018-12-19	SIAT3/SIAT1	160	80	160	80	80	160	80	320	320
A/England/138/2019	3C.3a	2019-01-28	SIAT3/SIAT1	80	80	80	40	80	640	40	40	80
A/England/154/2019	3C.3a	2019-02-07	SIAT2/SIAT1	80	80	80	40	80	640	40	320	80
A/England/185/2019	3C.3a	2019-02-08	SIAT2/SIAT1	160	40	80	40	80	640	<	320	160
A/England/155/2019	3C.3a	2019-02-08	SIAT2/SIAT1	40	40	80	40	80	640	<	160	320
A/England/222/2019	3C.3a	2019-02-20	SIAT1/SIAT1	40	40	80	<	40	320	<	160	320
A/England/157/2019	3C.3a	2019-02-25	SIAT2/SIAT1	40	80	80	40	80	320	<	320	320
A/England/156/2019	3C.3a	2019-02-26	SIAT2/SIAT1	40	80	80	40	80	320	<	320	320
					Vaccine SH 2018 NH 2018-19			Vaccine SH 2019				Vaccine NH 2019-20

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used) [1] < = <40

Sequences in phylogenetic trees

Table 4-3. Antigenic analysis of A(H3N2) viruses by HI - Summary

Viruses	Other information		Collection date	Haemagglutination inhibition titre								
				Post-infection ferret antisera								
		Passage history		A/HK 5738/14 MDCK	A/Bretagne 1413/17 SIAT	A/Singapore 0019/16 Egg 10^{-4}	A/La Rioja 2202/18 SIAT	A/Switz 8060/17 Egg	A/Eng 538/18 SIAT	A/Norway 3275/18 SIAT	NYMC X-327 A/Kansas/14 Egg	A/Kansas 14/17 SIAT
		Ferret number		St Judes F60/17[*1]	F01/18[*1]	F46/17[*1]	F26/18[*1]	F27/18[*1]	F31/18[*1]	F03/19[*1]	F16/19[*1]	F17/19[*1]
		Genetic group		3C.2a	3C.2a2	3C.2a1	3C.2a1b	3C.2a2	3C.3a	3C.2a1b	3C.3a	3C.3a
REFERENCE VIRUSES												
A/Hong Kong/5738/2014		3C.2a	2014-04-30	160	160	320	160	320	320	160	160	160
A/Bretagne/1413/2017		3C.2a2	2017-10-09	320	640	320	80	640	320	320	160	160
A/Singapore/INFIMH-16-0019/2016		3C.2a1	2016-04-14	160	80	1280	320	320	80	80	80	80
A/Switzerland/8060/2017	clone 57	3C.2a2	2017-12-12	160	1280	1280	160	2560	160	160	160	160
A/England/538/2018		3C.3a	2018-02-26	40	40	80	<	40	640	<	320	320
NYMC X-327 (A/Kansas/14/17)		3C.3a	2017-12-14	40	40	160	<	40	320	<	1280	320
A/Kansas/14/2017		3C.3a	2017-12-14	40	80	80	40	80	640	<	320	320
TEST VIRUSES												
Number of viruses tested*				37	37	37	37*	37	37	37*	37	37
No with titre reduction ≤2-fold				15	1		11		21	10		21
%				*40.5*	*2.7*				*56.8*			*56.8*
No with titre reduction =4-fold				18		2			7		5	3
%				*48.6*		*5.4*			*18.9*		*13.5*	*8.1*
No with titre reduction ≥8-fold				4	36	35		37	9		32	13
%				*10.9*	*97.3*	*94.6*		*100.0*	*24.3*		*86.5*	*35.1*
Subgroup 3C.2a1b viruses												
Number of viruses tested*				12	12	12	12*	12	12	12*	12	12
No with titre reduction ≤2-fold				6			6		2	5		3
%				*50.0*					*16.7*			*25.0*
No with titre reduction =4-fold				5					3			1
%				*41.7*					*25.0*			*8.3*
No with titre reduction ≥8-fold				1	12	12		12	7		12	8
%				*8.3*	*100.0*	*100.0*		*100.0*	*58.3*		*100.0*	*66.7*
Clade 3C.3a viruses												
Number of viruses tested*				23	23	23	23*	23	23	23*	23	23
No with titre reduction ≤2-fold				7			4		18	4		16
%				*30.5*					*78.3*			*69.6*
No with titre reduction =4-fold				13		1			3		4	2
%				*56.5*		*4.3*			*13.0*		*17.4*	*8.7*
No with titre reduction ≥8-fold				3	23	22		23	2		19	5
%				*13.0*	*100.0*	*95.7*		*100.0*	*8.7*		*82.6*	*21.7*
						Vaccine SH 2018 NH 2018-19		Vaccine SH 2019			Vaccine NH 2019-20	

* Homologous HI titres not available - only results for viruses yielding HI titres of ≥160 with the respective antisera are shown

Reference virus results are taken from Table 4-1. Summaries for each antiserum are based on fold-reductions observed on the days that HI assays were performed.

Figure 2. Phylogenetic comparison of influenza A(H3N2) HA genes



Influenza B virus analyses

Influenza B viruses represented only 2.9% of the samples received with collection dates after 31 August 2018 and were received from NICs in 14 countries: Austria, Croatia, Denmark, France, Greece, Iceland, Ireland, Italy, Luxembourg, Norway, Portugal, Slovenia, Sweden and the United Kingdom (Table 2). Of the small number received, 23 were B/Yamagata-lineage and 18 were B/Victoria-lineage.

Influenza B/Victoria-lineage

Ten B/Victoria-lineage viruses, eight from Norway and two from Ireland, have been tested by HI since the July 2019 characterisation report (Tables 5-1 to 5-2). Three patterns of reactivity in HI profiles were observed and of the eight viruses characterised genetically, one was clade 1A, two were group 1A(Δ2) and five were group 1A(Δ3) of African origin (see below).

A relatively small number (2 242 in total of which 1 951 were full length, as of 11 October 2019) of HA sequences for viruses collected from 1 September 2018 have been deposited in the GISAID EpiFlu database and the great majority of these have been from China and the USA, with only 84 (60 full length) from countries in Europe. All recent viruses that have data deposited in GISAID, continue to have HA genes that fall in the B/Brisbane/60/2008 clade (clade 1A; Figure 3), with all falling in a subclade defined by **HA1** amino acid substitutions **I117V**, **N129D** and **V146I** within clade 1A. Two groups within this subclade have deletions in the HA gene. A group that has spread worldwide, with the most recently circulating viruses having been reported mainly from the Americas and Madagascar, have HA genes encoding an **HA1** with deletion of residues **K162** and **N163** (1A(Δ2) in Figure 3). These viruses have additional substitutions of **D129G** and **I180V** in **HA1**, and **R151K** in **HA2**. The second group of B/Victoria-lineage viruses detected recently have HA genes encoding a deletion of three **HA1** amino acids, **K162**, **N163** and **D164** (1A(Δ3) in Figure 3); this group splits into an Asian subgroup, with viruses carrying additional substitutions of **I180T** and **K209N** in **HA1,** and a West African subgroup, with viruses carrying the **HA1** substitution **K136E**, often with additional HA1 substitutions of **G74E** and **E198G** (within the **197-199** glycosylation site) or **G133R**. The majority of recently collected B/Victoria-lineage viruses fall in the 1A(Δ3) West African subgroup and have been detected in countries worldwide, as is the case for all those reported from EU/EEA countries (Figure 3).

It was noted in the September 2018 characterisation report[4], and earlier ones, that the clade 1A viruses without deletions, the 1A(Δ2) group and the 1A(Δ3) subgroups are antigenically distinct from one another. Following the spread of 1A(Δ2) viruses a representative, B/Colorado/06/2017, was recommended for use in trivalent influenza vaccines for the 2018–19 and 2019–20 northern hemisphere [3, 1] and 2019 southern hemisphere [4] seasons. Recent predominance of 1A(Δ3) viruses of African origin led to recommendation of a representative (B/Washington/02/2019) for use in trivalent influenza vaccines for the 2020 southern hemisphere season [2].

Influenza B/Yamagata-lineage

Nine B/Yamagata-lineage viruses, two from England and seven from Norway, have been tested by HI since the July 2019 characterisation report (Tables 6-1 and 6-2). Antisera raised against three egg-propagated clade 3 viruses, B/Wisconsin1/2010 (former vaccine virus), B/Stockholm/12/2011, B/Phuket/3073/2013 (current vaccine virus) and B/Massachusetts/02/2012 (a former clade 2 vaccine virus), recognised seven, seven, six and six viruses, respectively, at titres within fourfold of the respective homologous titres. Similar results were seen with antisera raised against two recently isolated cell culture-propagated viruses, B/Mauritius/1791/2017 and B/Mauritius/I-762/2018. Antisera raised against three additional cell culture-propagated viruses with earlier collection dates, two clade 2 (B/Estonia/55669/2011 and B/Massachusetts/02/2012) and B/Phuket/3073/2013, recognised the test viruses less well (Tables 6-1 and 6-2).

A smaller number (1 008 in total of which 935 were full length, as of 11 October 2019) of B/Yamagata-lineage HA sequences for viruses collected from 1 September 2018 have been deposited in the GISAID EpiFlu database, and the great majority of these have been from China and the USA, with only 78 (53 full length) from countries in Europe. Figure 4 shows a phylogenetic analysis of the HA genes of recently circulating B/Yamagata-lineage viruses, with collection dates from 1 March 2019, that have data deposited in GISAID, with those analysed at the London WHO CC indicated; there are only ten from EU/EEA countries with collection dates falling within this period. HA sequences of all viruses collected in the 2017–2018 season, and since, carry HA genes in genetic clade 3, the B/Wisconsin/1/2010–B/Phuket/3073/2013 clade, with those from viruses collected after 31 August 2018 falling in a subgroup defined by **HA1 L172Q** and **M251V** amino acid substitutions compared to B/Phuket/3073/2013. Some subclustering of sequences, defined by specific amino acid substitutions (e.g. **HA1 S120T** or **G141R** or **D229N** or **D232N** [introducing a potential N-linked glycosylation site]), is occurring. It has been noted in previous characterisation reports for 2018 that none of these amino acid substitutions have any obvious antigenic effects based on HI assays using post-infection ferret antisera raised against egg-propagated B/Phuket/3073/2013 which has been recommended for inclusion in quadrivalent vaccines for the 2018–2019 and 2019–20 [3, 1] northern hemisphere and the 2019 and 2020 [4, 2] southern hemisphere seasons.

[4] European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, September 2018. Stockholm: ECDC; 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/ECDC-Flu-Characterisation-Report-Sep-2018.pdf

Table 5-1. Antigenic analysis of influenza B/Victoria-lineage viruses by HI

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre											
				Post-infection ferret antisera											
	Passage history			B/Bris 60/08 Egg	B/Bris 60/08 Egg	B/Malta 636714/11 Egg	B/Sth Aus 81/12 Egg	B/HK 514/09 MDCK	B/Ireland 3154/16 MDCK	B/Nord-West 1/16 MDCK	B/Norway 2409/17 MDCK	B/Colorado 06/17 MDCK	B/Colorado 06/17 Egg	B/Clv 1662/18 MDCK
				Sh 539, 540, 543, 544, 570, 571, 574[1,3]	F44/17[-2]	F29/13[-4]	F25/16[-4]	NIB F47/16[-2]	F15/16[-2]	F16/16[-2]	F40/17[-2]	F09/18[-4]	F11/18[-2]	F37/19[-2]
	Genetic group			1A	1A	1A	1A	1B	1A	1A	1A(Δ2)	1A(Δ2)	1A(Δ2)	1A(Δ3)
REFERENCE VIRUSES														
B/Brisbane/60/2008	1A	2008-08-04	E4/E4	1280	640	160	320	160	40	20	<	40	80	<
B/Malta/636714/2011	1A	2011-03-07	E4/E1	2560	640	320	320	320	40	40	<	10	160	<
B/South Australia/81/2012	1A	2012-11-28	E4/E2	5120	640	160	320	320	40	40	<	10	160	10
B/Hong Kong/514/2009	1B	2009-10-11	MDCK1/MDCK2	2560	80	40	40	160	80	80	<	<	<	<
B/Ireland/3154/2016	1A	2016-01-14	MDCK1/MDCK4	5120	80	<	20	160	80	160	<	<	<	<
B/Nordrhein-Westfalen/1/2016	1A	2016-01-04	C2/MDCK2	1280	40	<	<	80	10	80	<	<	<	<
B/Norway/2409/2017	1A(Δ2)	2017-04-27	MDCK1/MDCK3	80	20	<	<	<	<	<	40	40	160	<
B/Colorado/06/2017	1A(Δ2)	2017-02-05	MDCK1/MDCK2	160	40	<	<	10	<	<	80	80	160	<
B/Colorado/06/2017	1A(Δ2)	2017-02-05	E5/E2	640	160	20	20	20	<	<	20	40	320	<
B/Cote d'Ivoire/1662/2018	1A(Δ3)	2018-07-25	P0/MDCK3	80	40	<	10	<	<	<	<	10	40	40
TEST VIRUSES														
B/Ireland/21508/2019	1A(Δ2)	2019-02-22	MDCK1/MDCK1	160	20	<	<	<	<	<	40	80	160	<
B/Ireland/28115/2019	1A(Δ3)	2019-03-19	MDCK3/MDCK1	1280	80	<	40	20	<	<	<	40	160	40
					Vaccine[#]								Vaccine[$]	

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used):
[1] < = <40; [2] < = <10; [3] hyperimmune sheep serum; [4] < = <20; ND = Not Done

[#] B/Victoria-lineage virus recommended for use in trivalent vaccines NH 2017-18 and quadravalent vaccines SH 2018

[$] B/Victoria-lineage virus recommended for use in trivalent vaccines NH 2018-19, SH 2019 and NH 2019-20

Sequences in phylogenetic trees

Table 5-2. Antigenic analysis of influenza B/Victoria-lineage viruses by HI

Viruses	Other information	Passage history	Collection date	Passage history	Haemagglutination inhibition titre										
					Post-infection ferret antisera										
					B/Bris 60/08	B/Bris 60/08	B/Malta 636714/11	B/Sth Aus 81/12	B/HK 514/09	B/Ireland 3154/16	B/Nord-West 1/16	B/Norway 2409/17	B/Colorado 06/17	B/Colorado 06/17	B/CIV 1662/18
		Passage history			Egg	Egg	Egg	Egg	MDCK	MDCK	MDCK	MDCK	MDCK	Egg	MDCK
		Ferret number			Sh 539, 540, 543, 544, 570, 571, 574[*1,3]	F44/17[*2]	F29/13[*2]	F25/16[*4]	NIB F47/16[*2]	F15/16[*2]	F16/16[*2]	F40/17[*2]	F09/18[*4]	F11/18[*2]	F37/19[*4]
		Genetic group			1A	1A	1A	1A	1B	1A	1A	1A(Δ2)	1A(Δ2)	1A(Δ2)	1A(Δ3)
REFERENCE VIRUSES															
B/Brisbane/60/2008		1A	2008-08-04	E4/E4	2560	640	320	640	160	40	40	<	40	160	<
B/Malta/636714/2011		1A	2011-03-07	E4/E1	2560	640	320	320	160	40	20	<	20	80	<
B/South Australia/81/2012		1A	2012-11-28	E4/E2	2560	1280	320	640	320	80	40	<	40	160	<
B/Hong Kong/514/2009		1B	2009-10-11	MDCK1/MDCK2	2560	320	160	80	160	80	80	<	20	<	<
B/Ireland/3154/2016		1A	2016-01-14	MDCK1/MDCK4	2560	40	80	40	80	160	160	<	<	<	<
B/Nordrhein-Westfalen/1/2016		1A	2016-01-04	C2/MDCK2	1280	40	40	40	40	80	80	<	<	<	<
B/Norway/2409/2017		1A(Δ2)	2017-04-27	MDCK1/MDCK3	80	<	<	<	<	<	<	80	80	160	<
B/Colorado/06/2017		1A(Δ2)	2017-02-05	MDCK1/MDCK2	80	<	<	<	<	<	<	80	80	320	<
B/Colorado/06/2017		1A(Δ2)	2017-02-05	E5/E2	1280	320	80	80	20	<	<	40	160	640	<
B/Cote d'Ivoire/1662/2018		1A(Δ3)	2018-07-25	P0/MDCK3	80	20	10	20	<	<	<	<	20	40	40
TEST VIRUSES															
B/Norway/1410/2019		1A(Δ3)	2019-03-18	MDCK1/MDCK1	40	<	40	40	<	<	<	<	40	80	40
B/Norway/1717/2019		1A(Δ3)	2019-04-12	MDCK1/MDCK1	20	<	40	<	<	<	<	<	40	<	40
B/Norway/2092/2019			2019-05-24	MDCK1/MDCK1	20	<	40	<	<	<	<	<	40	40	40
B/Norway/2116/2019		1A(Δ3)	2019-06-06	MDCK1/MDCK1	80	<	40	40	<	<	<	<	20	160	80
B/Norway/2115/2019		1A	2019-06-12	MDCK1/MDCK1	320	40	40	80	80	80	40	<	20	<	<
B/Norway/2225/2019		1A(Δ2)	2019-07-25	MDCK1/MDCK1	40	<	40	<	<	<	<	80	320	320	<
B/Norway/2211/2019			2019-07-28	MDCK1/MDCK1	40	<	40	<	<	<	<	20	20	<	40
B/Norway/2210/2019		1A(Δ3)	2019-07-31	MDCK1/MDCK1	320	<	80	<	<	<	<	20	40	80	80
						Vaccine[#]								Vaccine[$]	

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used):
[1] < = <40; [2] < = <10; [3] hyperimmune sheep serum; [4] < = <20; ND = Not Done

[#] B/Victoria-lineage virus recommended for use in trivalent vaccines NH 2017-18 and quadravalent vaccines SH 2018

[$] B/Victoria-lineage virus recommended for use in trivalent vaccines NH 2018-19, SH 2019 and NH 2019-20

Sequences in phylogenetic trees

Figure 3. Phylogenetic comparison of influenza B/Victoria-lineage HA genes



Table 6-1. Antigenic analysis of influenza B/Yamagata-lineage viruses by HI

Viruses	Other information		Collection date	Passage history	Haemagglutination inhibition titre									
					Post-infection ferret antisera									
		Passage history			B/Phuket 3073/13	B/Estonia 55669/11	B/Mass 02/12	B/Mass 02/12	B/Wis 1/10	B/Stock 12/11	B/Phuket 3073/13	B/Phuket 3073/13	B/Maur 1791/17	B/Maur I-762/18
		Ferret number			Egg SH614[*1,3]	MDCK F39/17[*2]	MDCK F10/16[*2]	Egg F06/17[*2]	Egg F36/15[*2]	Egg F05/17[*2]	MDCK F27/15[*2]	Egg F25/17[*2]	MDCK F04/18[*2]	MDCK F05/19[*2]
		Genetic Group			3	2	2	2	3	3	3	3	3	3
REFERENCE VIRUSES														
B/Estonia/55669/2011		2	2011-03-14	MDCK2/MDCK3	320	40	40	160	10	<	<	40	<	40
B/Massachusetts/02/2012		2	2012-03-13	MDCK1/C2/MDCK4	1280	160	640	640	80	80	20	320	40	320
B/Massachusetts/02/2012		2	2012-03-13	E3/E4	320	20	20	320	20	40	<	80	<	10
B/Wisconsin/1/2010		3	2010-02-20	E3/E2	640	<	20	320	20	40	<	80	<	40
B/Stockholm/12/2011		3	2011-03-28	E4/E1	320	<	20	160	10	40	<	80	<	20
B/Phuket/3073/2013		3	2013-11-21	MDCK2/MDCK3	2560	80	320	320	40	160	40	160	80	640
B/Phuket/3073/2013		3	2013-11-21	E4/E3	640	<	10	160	20	40	<	80	<	40
B/Mauritius/1791/2017		3	2017-09-20	MDCK1/MDCK4	640	<	20	160	40	<	<	40	20	80
B/Mauritius/I-762/2018		3	2018-09-02	MDCK1/MDCK3	640	<	20	80	40	<	<	40	20	160
TEST VIRUSES														
B/England/247/2019		3	2019-03-08	SIAT1/MDCK1	640	<	20	40	10	<	10	40	<	80
B/England/152/2019		3	2019-03-19	SIAT2/MDCK1	1280	80	160	160	40	80	20	160	80	320
												Vaccine[#]		

* Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used):
1 < = <40; 2 < = <10; 3 hyperimmune sheep serum

[#] B/Yamagata-lineage virus recommended for use in quadravalent vaccines NH 2018-19, SH 2019 and NH 2019-20

Sequences in phylogenetic trees

Table 6-2. Antigenic analysis of influenza B/Yamagata-lineage viruses by HI

Viruses	Other information	Collection date	Passage history	Haemagglutination inhibition titre											
				Post-infection ferret antisera											
	Passage history			B/Phuket 3073/13 Egg SH614[*1,3]	B/Estonia 55669/11 MDCK F39/17[*2]	B/Mass 02/12 MDCK F10/16[*2]	B/Mass 02/12 Egg F06/17[*2]	B/Wis 1/10 Egg F36/15[*2]	B/Stock 12/11 Egg F05/17[*2]	B/Phuket 3073/13 MDCK F27/15[*2]	B/Phuket 3073/13 Egg F25/17[*2]	B/Maur 1791/17 MDCK F04/18[*2]	B/Maur I-762/18 MDCK F05/19[*2]
	Ferret number			3	2	2	2	3	3	3	3	3	3
	Genetic Group												
REFERENCE VIRUSES													
B/Estonia/55669/2011	2	2011-03-14	MDCK2/MDCK3	640	80	40	160	20	20	<	80	40	80
B/Massachusetts/02/2012	2	2012-03-13	MDCK1/C2/MDCK4	2560	160	320	640	160	160	40	320	40	320
B/Massachusetts/02/2012	2	2012-03-13	E3/E3	320	10	10	160	10	20	<	40	<	20
B/Wisconsin/1/2010	3	2010-02-20	E3/E2	1280	<	10	160	40	40	<	160	40	40
B/Stockholm/12/2011	3	2011-03-28	E4/E2	640	<	10	80	20	80	<	160	20	40
B/Phuket/3073/2013	3	2013-11-21	MDCK2/MDCK3	2560	160	320	320	80	160	80	320	320	1280
B/Phuket/3073/2013	3	2013-11-21	E4/E3	640	<	10	80	20	40	<	160	40	40
B/Mauritius/1791/2017	3	2017-09-20	MDCK1/MDCK4	1280	<	20	80	20	40	10	160	160	160
B/Mauritius/I-762/2018	3	2018-09-02	MDCK1/MDCK3	1280	20	20	80	20	40	10	160	160	160
TEST VIRUSES													
B/Norway/305/2019	3	2019-01-15	MDCK1/MDCK1	320	<	<	<	<	<	<	<	<	<
B/Norway/1469/2019	3	2019-03-23	MDCK1/MDCK1	2560	20	40	80	20	80	10	160	160	320
B/Norway/1494/2019	3	2019-03-25	MDCK1	320	<	<	40	10	20	<	20	20	20
B/Norway/1931/2019	3	2019-04-27	MDCK1	640	<	<	40	10	20	<	80	80	80
B/Norway/1954/2019	3	2019-05-02	MDCK1	640	<	<	40	10	20	<	40	40	80
B/Norway/2051/2019	3	2019-05-13	MDCK1/MDCK1	640	<	<	40	20	20	<	40	40	80
B/Norway/2134/2019	3	2019-06-06	MDCK1/MDCK1	640	<	<	<	<	<	<	10	<	<
												Vaccine[#]	

*Superscripts refer to antiserum properties (< relates to the lowest dilution of antiserum used):
1 < = <40; 2 < = <10; 3 hyperimmune sheep serum

[#] B/Yamagata-lineage virus recommended for use in quadravalent vaccines NH 2018-19, SH 2019 and NH 2019-20

Sequences in phylogenetic trees

Figure 4. Phylogenetic comparison of influenza B/Yamagata-lineage HA genes



Summaries of data submitted to TESSy

Genetic characterisation

For the 2018–19 season, as of week 39/2019, 4180 viruses had been characterised genetically and ascribed to a genetic clade:

- 1 907 A(H1N1)pdm09 were subclade 6B.1, represented by the vaccine virus A/Michigan/45/2015, with a further three attributed to a subgroup not listed;
- 2 202 were A(H3N2) viruses, with 1 471 being subgroup 3C.2a1b represented by A/Alsace/1746/2018, 70 being subclade 3C.2a2 represented by A/Switzerland/8060/2017, 34 being subclade 3C.2a3 represented by A/Cote d'Ivoire/544/2016, 550 being clade 3C.3a represented by A/England/538/2018, 57 being subclade 3C.2a1 represented by A/Singapore/16-0019/2016, five being clade 3C.2a represented by A/Hong Kong/4801/2014, nine being subgroup 3C.2a1a represented by A/Greece/4/2017, and six were attributed to a subgroup not listed in current TESSy reporting categories;
- 32 were B/Yamagata-lineage clade 3 represented by the vaccine virus B/Phuket/3073/2013;
- 36 were B/Victoria-lineage viruses, with six being clade 1A represented by B/Brisbane/60/2008, seven being subclade 1A.Δ2 with a two amino acid deletion in HA represented by the vaccine virus B/Colorado/06/2017, and 23 being subclade 1A.Δ3 with a three amino acid deletion in HA represented by B/Hong Kong/269/2017.

Antiviral susceptibility

For viruses collected in the course of the 2018–19 season, as of week 20/2019, 1 668 A(H1N1)pdm09, 1 121 A(H3N2), and 35 type B have been tested for susceptibility to neuraminidase inhibitors. Eight A(H1N1)pdm09 viruses carried NA H275Y amino acid substitution indicative of highly reduced inhibition (HRI; confirmed phenotypically for three), and an additional three showed evidence of reduced inhibition (RI) by oseltamivir in phenotypic assays. One type B virus showed evidence of RI by oseltamivir and zanamivir. There was no update for the period week 21–39/2019.

At the WIC for this season, 1 096 viruses from EU/EEA countries have been assessed phenotypically against oseltamivir and zanamivir: 560 A(H1N1)pdm09, 485 A(H3N2), 27 B/Victoria-lineage and 24 B/Yamagata-lineage. All but five viruses showed normal inhibition (NI) by the two neuraminidase inhibitors. B/Norway/3241/2018 (Victoria-lineage) showed RI by the inhibitors and the NA gene encoded D197N amino acid substitution. A/Latvia/03-0738053/2019 (H3N2) showed RI by zanamivir and sequencing revealed NA D151D/N polymorphism and V165I amino acid substitution. Two A(H1N1)pdm09 viruses, A/Cyprus/919/2019 and A/Trnava/535/2019, showed HRI by oseltamivir and their NA genes encoded N295S and H275Y amino acid substitutions, respectively. A third A(H1N1)pdm09 virus, A/Denmark/2697/2019, showed RI by zanamivir and sequencing revealed NA Q136K/Q and D151D/E amino acid polymorphisms.

Influenza A(H7N9) virus

On 1 April 2013, the World Health Organization (WHO) Global Alert and Response [5] reported that the China Health and Family Planning Commission notified the WHO of three cases of human infection with influenza A(H7N9). A description of the characteristics of H7N9 viruses can be found on the WHO website [6]. Increased numbers of cases were reported over the course of the following seasons and cases were reported in 2017, including the fifth (2016–17) and largest wave to date, which included the emergence of highly pathogenic avian influenza (HPAI) strains that have caused some zoonoses, though few human cases were reported during the 2017–18 season [7]. WHO posted an analysis of information on A(H7N9) viruses on 10 February 2017 [8]; a summary and assessment of influenza viruses at the human-animal interface on 27 September 2019 reports that no new cases of human infection had been detected since the 24 June report and indicates that there have been no publicly available reports from animal health authorities in China of influenza A(H7N9) virus detections in animals in recent months [9]. The most recent human case was detected in mid-March 2019 [10]. The latest overview of avian influenza by ECDC in collaboration with the European Food Safety Authority and the EU Reference Laboratory for Avian Influenza was published on 27 September 2019 and can be found on the ECDC website [11].

Influenza A(H5) virus

The most recent monthly risk assessment of influenza at the human–animal interface was published by WHO on 27 September 2019, indicating that various A(H5Nx) subtypes continue to be detected in birds in Africa, Europe and Asia, with a new case of human infection with an A(H5N6) virus being reported by China on18 august [9]. No new human cases of A(H5N1) infection have been detected since that in Nepal in March, where there have been reports of A(H5N1) infection in domestic birds since February 2019, this being the first human case of A(H5N1) infection reported to WHO since 2017 [12]. On 18 November 2016, ECDC published a rapid risk assessment related to outbreaks of highly pathogenic avian influenza H5N8 viruses in Europe [13]. As described above, the EU Reference Laboratory for Avian Influenza, in collaboration with ECDC and the European Food Standards Agency, published on 27 September 2019 the latest overview of avian influenza, which can be found on the ECDC website [11].

WHO CC reports

A description of results generated by the London WHO CC at the WIC and used at the most recent WHO vaccine composition meeting (held in Geneva, Switzerland 23-27 September 2019), and previous ones, can be found at:

https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports (accessed 9 October 2019)

Note on the figures

The phylogenetic trees were constructed using RAxML, drawn using FigTree and annotated using Adobe Illustrator. The bars indicate the proportion of nucleotide changes between sequences. Reference strains are viruses to which post-infection ferret antisera have been raised. The colours indicate the month of sample collection. Isolates from WHO NICs in EU/EEA countries are marked (#). Sequences for most viruses from non-EU/EEA countries were recovered from the GISAID EpiFlu database. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from the GISAID EpiFlu database, which were downloaded for use in the preparation of this report (all submitters of data may be contacted directly via the GISAID website), along with all laboratories who submitted sequences directly to WHO CC London.

References

1. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season [accessed 2 October 2019]. Available from: https://apps.who.int/iris/bitstream/handle/10665/311441/WER9412-141-150.pdf
2. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2020 southern hemisphere influenza season [accessed 9 October 2019]. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201909_recommendation.pdf
3. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Wkly Epidemiol Rec. 2018 Mar 23;93(12):133-152. Available from: http://apps.who.int/iris/bitstream/handle/10665/260550/WER9312.pdf
4. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season. Wkly Epidemiol Rec. 2018 Oct 19;93(42):553-576. Available from: http://apps.who.int/iris/bitstream/handle/10665/275475/WER9342.pdf
5. World Health Organization. Emergencies preparedness, response – Human infection with influenza A(H7N9) virus in China. 1 April 2013 [internet]. Geneva: WHO; 2013 [accessed 10 October 2019]. Available from: http://www.who.int/csr/don/2013_04_01/en/index.html
6. World Health Organization. Influenza – Avian influenza A(H7N9) virus [internet]. Geneva: WHO; 2017 [accessed 10 October 2019]. Available from: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/
7. World Health Organization. Emergencies preparedness, response –Human infection with avian influenza A(H7N9) virus – China [internet]. Geneva: WHO; 2017 [accessed 10 October 2019]. Available from: http://www.who.int/csr/don/26-october-2017-ah7n9-china/en/
8. World Health Organization. Analysis of recent scientific information on avian influenza A(H7N9) virus. 10 February 2017 [internet]. Geneva: WHO, 2017 [accessed 10 October 2019]. Available from: http://www.who.int/influenza/human_animal_interface/avian_influenza/riskassessment_AH7N9_201702/en
9. World Health Organization. Influenza at the human-animal interface. Summary and assessment, 25 June to 27 September 2019 [internet]. Geneva: WHO, 2019. Available from: https://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_27_09_2019.pdf
10. World Health Organization. Influenza at the human–animal interface. Summary and assessment, 13 February to 9 April 2019 [internet]. Geneva: WHO; 2019. Available from: https://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_09_04_2019.pdf
11. European Centre for Disease Prevention and Control, European Food Safety Authority, European Union Reference Laboratory for Avian influenza. Avian influenza overview, February – August 2019. Parma and Stockholm: EFSA, ECDC; 2019. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/avian-influenza-overview-february-august-2019.pdf
12. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2019. Geneva: WHO; 2019. Available from: https://www.who.int/influenza/human_animal_interface/2019_09_27_tableH5N1.pdf
13. European Centre for Disease Prevention and Control. Outbreak of highly pathogenic avian influenza A(H5N8) in Europe – 18 November 2016. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/risk-assessment-avian-influenza-H5N8-europe.pdf